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Abstract 
 
 The emergence of CTX-M class-A extended-spectrum β-lactamases, which 
confer resistance to second and third-generation cephalosporins, poses a serious health threat to 
the public. CTX-M β-lactamases use a catalytic serine to hydrolyze the β-lactam ring.  
Specifically, the hydrolysis reaction catalyzed by CTX-M β-lactamase proceeds through a pre-
covalent complex, a high-energy tetrahedral acylation intermediate, a low-energy acyl-enzyme 
complex, a high-energy tetrahedral deacylation intermediate after attack via a catalytic water, 
and lastly, the hydrolyzed β-lactam ring product which is released from the enzyme complex.  
The crystallographic structure of CTX-M at sub-angstrom resolution has enabled us to study 
enzyme catalysis as well as perform computational molecular docking in our efforts to develop 
new inhibitors against CTX-M.  The goal of this project was to determine the hydrogen bonding 
network and proton transfer process at different stages of the reaction pathway as well as develop 
novel inhibitors against CTX-M β-lactamases.  The results I have obtained from the project have 
elucidated the catalytic mechanism of CTX-M β-lactamase in unprecedented detail and 
facilitated the development of novel inhibitors for antibiotic drug discovery.    
The first aim of the project focused on developing high affinity inhibitors against class A 
β-lactamase using a structure-based drug discovery approach, which ultimately led to the 
identification of CTX-M9 inhibitors with nanomolar affinity.  Compound design was based on 
the initial use of computational molecular docking results along with x-ray crystal structures with 
known inhibitors bound in the active site.  In addition, chemical synthesis was used to build and 
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extend the existing inhibitor scaffold to improve affinity to CTX-M9 and related serine β-
lactamases.  Through a fragment-based screening approach, we recently identified a novel non-
covalent tetrazole-containing inhibitor of CTX-M.   Structure-based design was used to improve 
the potency of the original tetrazole lead compound more than 200-fold with the use of small, 
targeted structural modifications.  A series of compounds were used to probe specific binding 
hotspots present in CTX-M.  The designed compounds represent the first nM-affinity non-
covalent inhibitors of a class A β-lactamase.  The complex structures of these potent compounds 
have been solved using high resolution x-ray crystallography at ~ 1.2-1.4 Å, which provides 
valuable insight about ligand binding and future inhibitor design against class A β-lactamases.  
Specifically, the first aim of the project was to use ultra-high resolution x-ray 
crystallography to study β-lactamase catalysis.   Through the use of ultra-high resolution x-ray 
crystallography with non-covalent and covalent inhibitors, I was able to structurally characterize 
the critical stages of the enzyme mechanism.  Here we report a series of ultra-high resolution x-
ray crystallographic structures that reveal the proton transfer process for the early stages of the 
class A β-lactamase catalytic mechanism.  The structures obtained include an a 0.89 Å crystal 
structure of CTX-M β-lactamase in complex with a recently-developed 89 nM non-covalent 
inhibitor, and a 0.80 Å structure in complex with an acylation transition state boronic acid 
inhibitor. Nearly all the hydrogen atoms in the active site, including those on the ligand, polar 
protein side chains and catalytic water, can be identified in the unbiased difference electron 
density map.  Most surprisingly, compared with a previously determined 0.88 Å apo structure 
determined under the same conditions, the hydrogen-bonding network has undergone a series of 
reshuffling upon the binding of the non-covalent ligand.  Two key catalytic residues, Lys73 and 
Glu166, appear to have both changed from a charged state to being neutral.  Interestingly, 
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structural evidence suggests the presence of a low barrier hydrogen bond (LBHB) shared 
between Lys73 and Ser70. These unprecedented detailed snapshots offer direct evidence that 
ligand binding can alter the pKa's of polar protein side chains and their affinities for 
protons.  Such effects can be a common mechanism utilized by enzymes to facilitate the proton 
transfer process of a reaction pathway.  They also have important implications for computational 
modeling of protein-ligand interactions.  Ultra-high resolution x-ray crystallography allowed us 
to determine the hydrogen atom positions for key active site residues involved in catalysis.  As a 
result, the ability to characterize the hydrogen bonding network led to the determination of the 
specific proton transfer process that occurs during the reaction stages of the CTX-M β-lactamase 
mechanism.  Overall, the results from this project demonstrate the effectiveness of using ultra 
high resolution x-ray crystallography as a useful tool to study enzyme catalysis as well as 
develop and discover novel inhibitors.   
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Chapter 1 
 
Introduction 
 
Note to Reader 
 Portions of this chapter have been previously published (1) (Nichols et al., 2014) in 
Future Med. Chem. (2014) 6(4), 413-427 and have been reproduced with permission from Future 
Science Ltd (See Appendix 1).   
 
β-Lactam Antibiotic Resistance 
 Traditionally, β-lactam compounds, such as penicillins, are the most widely used 
antibiotics due to their ability to inhibit bacterial cell wall synthesis (2, 3).  The bacterial cell 
wall is composed primarily of a cross-linked, mesh-like, peptidoglycan polymer, in which a 
disaccharide bearing a pentapeptide is the basic unit (4, 5). Specifically, β-lactam antibiotics 
target the transpeptidases of penicillin binding proteins (PBPs), which use the pentapeptide as 
their substrate and are essential for peptidoglycan synthesis (6-8).  The β-lactam antibiotics react 
with PBPs because the β-lactam ring mimics the D-Ala-D-Ala group at the terminus of the 
pentapeptide.  As a result, β-lactam compounds form a stable acyl-enzyme bond with the 
catalytic serine and irreversibly block the active site from access by the peptide substrate (9-11).  
The widespread emergence of bacterial resistance against β-lactam antibiotics, particularly in 
Gram-negative bacteria, is mainly due to the production of β-lactamase, which is responsible for 
the breakdown of the β-lactam ring of various antibiotics, such as penicillin and cephalosporin.  
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Beta-lactamase is comprised of four families, classes A through D, in which class A and C are 
most commonly observed in the clinical setting (12, 13).   Since the discovery of penicillin, new 
compounds have been developed to evade resistance against β-lactam antibiotics, such as the 
cephalosporins and carbepenems (Fig. 1).   Unfortunately, bacteria have acquired resistance 
mechanisms by evolving β-lactamase activity against these extended spectrum antibiotics, 
rendering the majority of these compounds useless. Members of class B are metallo-enzymes, 
and require a catalytic metal ion, such as zinc to function (12) .  Classes, A, C, and D are serine 
β-lactamases and they use a catalytic serine to hydrolyze the β-lactam ring, forming an acyl-
enzyme complex similar to the PBPs (8, 12-14).  However, unlike the PBPs, the serine β-
lactamases catalyze a second hydrolytic deacylation reaction that involves the release of the 
antibiotic (10, 12, 14) (Fig. 2).  The Class A β-lactamase known as CTX-M, is particularly 
effective against extended spectrum β-lactam antibiotics, such as cefotaxime, in addition to its 
activity against first-generation penicillins and cephalosporins (14-18). CTX-M, which was first 
discovered in the 1990s (14), has become the most frequently observed extended spectrum β-
lactamases (ESBLs) in many regions of the world.  As a result, treatment options for bacterial 
infections will continue to be limited due to highly effective ESBLs such as CTX-M.   
 
β-Lactamase Classification  
 Beta-lactamases are classified into classes A, B, C, and D, according to their amino acid 
sequence and the functional aspects of the enzymes.  The class A, C, and D β-lactamases are 
grouped based on the conservation of their amino acid sequence and their ability to hydrolyze 
substrates in a similar fashion (12, 14).  Specifically these groups of enzymes hydrolyze the β-
lactam ring via a catalytic serine residue, forming an acyl enzyme complex (12, 14).  On the 
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other hand, class B β-lactamases are metalloenzymes, and use a metal-ion such as an active-site 
zinc which is used to catalyze the hydrolysis of the beta-lactam ring (12, 14). 
 Among the four classes of β-lactamases, classes A through C occur the most frequently 
(12, 13).  The third generation cephalosporins such as cefotaxime and ceftazidime, were 
introduced in the early 1980s to combat resistant Gram-negative infections caused by class A, C, 
and D β-lactamase producing bacteria,  As  a result, the repeated use of these drugs led to the 
emergence of the ESBLs, and are comprised of mainly class A and D enzymes.  Interestingly, 
the class A CTX-M β-lactamases is the most widespread and frequently occurring ESBLs 
amongst the class A β-lactamases.   
  
 
Class A β-Lactamase Mechanism 
 The class A β-lactamase CTX-M contains a catalytic Ser70 that forms a covalent bond 
with the β-lactam ring during the reaction (12, 13, 19).  The hydrolysis reaction catalyzed by 
CTX-M proceeds through a pre-covalent complex, a high-energy tetrahedral acylation 
intermediate, a low-energy acyl-enzyme complex, a high-energy tetrahedral deacylation 
intermediate after attack via a catalytic water, and lastly, the hydrolyzed β-lactam ring product 
which is released from the enzyme complex (Fig. 3) (20, 21).  The complexity of this enzyme 
and the reaction steps involved have called into question the identity of the catalytic base 
responsible for activating the serine to attack the beta-lactam ring.  However, there is a general 
concensus that Glu166 is often identified as the catalytic base responsible for activating the 
hydrolytic water during the deacylation step of the reaction.   Studies of the sub-Ångstrom 
resolution 0.88 Å X-ray crystal structure of apo CTX-M-9 have suggested the acting catalytic 
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base during acylation to be Glu166 via a catalytic water, while other studies support the 
hypothesis of Lys73 abstracting a proton directly from Ser70 (Fig. 4b-c) (22-24).  Specifically, 
the mechanism by which β-lactamase hydrolyzes the beta-lactam ring involves a complex 
reaction pathway.  Not surprisingly, before our findings, many questions still remained regarding 
the details of how this complex enzyme functions.  Likewise, little was known about the 
hydrogen bonding network and proton transfer process that occurs during the enzyme 
mechanism reaction under CTX-M β-lactamase.   
 
β-Lactamase Inhibitors   
 Since the discovery of penicillins, many new β-lactam drugs, such as cephalosporins and 
carbapenems, have been developed that can evade and/or inhibit β-lactamase hydrolysis, with 
many acting as mechanism-based suicide substrates for PBPs and/or β-lactamases (Fig. 5) (25). 
Almost invariably however, mutations or new enzymes have emerged that enable the recognition 
and hydrolysis of the latest generation of β-lactam antibiotics. The CTX-M Class A β-
lactamases, the most common of the ESBLs, continue to evolve enhanced activity against the 
third generation cephalosporins (14, 21, 26-28).  Other Class A ESBLs are also of increasing 
concern clinically (28, 29).  In addition, in recent years, carbapenemase activity has been 
observed in many Class A, B and D enzymes, rendering even the venerable carbapenems 
ineffective for treating bacterial infections in life threatening situations (30-32).  
The use of a β-lactamase inhibitor in combination with a β-lactam antibiotic is a well-
established strategy to counter resistance (33). Classical β-lactamase inhibitors such as 
clavulanate (Fig. 5), tazobactam, and sulbactam have been of significant clinical value in this 
regard, but these inhibitors are primarily effective against Class A enzymes and therefore are not 
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broadly useful for countering the diversity of β-lactamase enzymes present today.  These 
classical inhibitors also contain a β-lactam ring and, as a result, they are susceptible to resistance 
resulting from up-regulation of β-lactamase expression, new β-lactamase acquisition, and other 
mechanisms that have evolved over millions of years of competition between bacteria and β-
lactam-producing microorganisms(34-37).  These limitations, as well as the widespread presence 
of ESBLs and carbapenemases in multi-drug-resistant Gram-negative pathogens, have motivated 
the search for new classes of β-lactamase inhibitors, as reviewed recently by Drawz and 
Bonomo(33).  Two notable examples include Avibactam (previously known as NXL104)(38-40), 
and RPX7009(41, 42) (Fig. 5).  These new β-lactamase inhibitors can form a stable covalent 
bond with the catalytic serine in a wide range of β-lactamases, and thus possess broad-spectrum 
activity. Avibactam is currently in late-stage clinical trials as cephalosporin or carbapenem 
combinations.  RPX7009 is undergoing phase I trials in combination with a carbapenem, 
biapenem.  These recent successes demonstrate that novel, non-β-lactam compounds can be 
employed clinically to inhibit β-lactamases in resistant bacteria(43-46).  
Developing novel antimicrobial chemotypes is crucial for addressing bacterial resistance, 
yet traditional high-throughput screening (HTS) against isolated drug targets has proven largely 
ineffective (47, 48).  For example, 51 out of 67 HTS campaigns on antibacterial targets at 
GlaxoSmithKline (GSK) failed to yield any hits, and only 5 from the remaining 16 generated 
leads suitable for further optimization (47).  HTS against whole bacteria, however, has produced 
at least one new class of drugs, the oxazolidinones (49, 50). A problem with existing HTS 
screening libraries is their limited size and biased chemical composition favoring GPCR (G-
protein coupled receptor)- and kinase-type ligands (51-54). Fragment-based approaches instead 
focus on lower molecular weight (MW <250 Dalton) compounds that target sub-pockets of a 
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binding site (55), usually with higher ‘ligand efficiency’ (binding energy per heavy atom) than 
typical HTS hits.  Fragments, because of their smaller size, provide a more complete 
representation of chemical space (56-62).   This drug discovery paradigm often offers an 
efficient lead optimization strategy through growing or merging of structurally characterized 
fragments into high-affinity compounds (63), and has led to several drug candidates in Phase 
II/III trials and one FDA-approved drug (64). 
 
HTS vs. Fragment-Based Methods in Inhibitor Design Against β-Lactamases 
HTS has produced mixed results against serine and metallo β-lactamases.  For serine β-
lactamases, HTS has consistently failed to yield meaningful lead compounds.  The HTS 
campaign by GSK against P99 Class C β-lactamase did not uncover any hits out of half a million 
compounds screened (47).  Another screen of ~70,000 compounds from the NIH Chemical 
Genomics Center (NCGC) against AmpC Class C β-lactamase led to 12 promiscuous covalent 
inhibitors but no specific reversible inhibitors (48).   Computational docking methods were 
slightly more successful against AmpC, producing two inhibitors from 16 compounds chosen 
from the same NCGC library (48), and three inhibitors from an earlier effort using 56 molecules 
selected from 200,000 compounds of Available Chemical Database (ACD) (65).  Similar efforts 
using the ACD against TEM Class A β-lactamases led to two high µM allosteric inhibitors(66).    
In contrast to this poor track record against serine β-lactamases, HTS has been applied 
successfully to identify novel inhibitors against metallo β-lactamases.   Although screening of 
the GSK library against CfiA metallo β-lactamase did not lead to any hits, HTS at Merck (67, 
68), Meiji Seika Kaisha Ltd (69), and academic groups (70, 71) all identified novel chemotypes 
using large libraries containing hundreds of thousands of compounds.  One reason for this 
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success may be the presence in the screening compounds of functional groups such as thiol, 
carboxylate, and tetrazole that can form strong interactions with the zinc center in these metallo-
enzymes.  This has led to the screening of more focused libraries containing some of these 
chemotypes (72-74).  The relatively shallow and open active sites of metallo β-lactamases also 
reduce the chances of steric clashes with potential inhibitors (75-77).  By comparison, there is no 
single feature in serine β-lactamases that can by itself contribute binding affinity comparable to 
the metal-ligand interaction in Class B enzymes.  It thus becomes less likely that one will find 
HTS hits of reasonable affinity for serine β-lactamases, since multiple binding interactions 
would need to be satisfied.   However, these very features of serine β-lactamases (multiple 
binding sub-sites) make them especially attractive targets for fragment-based approaches. 
Fragment-based lead discovery (FBLD) has proven in the past several years to be a very 
promising method to develop new inhibitors against both serine and metallo β-lactamases, 
including CTX-M Class A (78, 79), AmpC Class C (45, 80) and IMP-1 Class B enzymes (81, 
82).  It has been successfully applied in both lead identification to uncover novel chemotypes for 
non-covalent inhibitors, and in lead optimization to probe additional binding hot spots for 
covalent inhibitors.  Several trends have emerged from these studies.  
First, the availability of high quality structural data has played a crucial role in this area (83).  
The majority of β-lactamase crystals can diffract to very high resolutions in X-ray 
crystallographic analysis.  Some extraordinary examples include Class A enzymes TEM-1 (0.85 
Å)(84), CTX-M-9 (0.88 Å) (20), SHV-2 (0.9 Å) (85), KPC-2 (1.23 Å) (86), Class C enzymes 
AmpC (1.07 Å) (22), Class D enzymes OXA-10 (1.35 Å, PDB 2X02), and Class B enzymes 
NDM-1 (1.05 Å, PDB 4HL2).  Accordingly, this group of enzymes is ideally suited to the FBLD 
approach, with the high resolution structures not only providing better templates for 
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computational modeling, but also allowing more accurate determination of fragment binding 
modes.  The low binding affinity of fragment inhibitors often results in their low occupancy in 
complex crystals and weak signals in electron density maps.  For lower resolution crystal 
structures including those around 2.0 Å, it usually means significant ambiguities in the binding 
conformations of fragment inhibitors.  The high quality of β-lactamase crystal structures 
overcomes this difficulty and the improved accuracy is particularly useful in elaborating 
fragments into leads via growing or merging fragments (45, 78-80).   
Second, computational docking technology has matured to the point that it is now very 
useful for prioritizing fragments for experimental testing (87, 88).  The low binding affinity of 
fragment inhibitors means that they have to be tested at very high concentrations, usually in the 
high µM or low mM range.  Traditional biochemical assays are often plagued by artifacts when 
performed in these concentration ranges and so biophysical methods such as NMR, X-ray 
crystallography, and SPR have more often been deployed to screen fragment compounds in a 
low throughput fashion, usually testing up to only a few thousand molecules in each screen (83, 
89-91).  Computational docking allows a rapid initial prioritization of compounds from the 
approximately half a million commercially available fragment-like compounds (92), significantly 
expanding the overall chemical space being sampled in a fragment screening campaign. Despite 
initial skepticism, computational screens have uncovered novel fragment inhibitors against both 
Class A and Class C β-lactamases at a hit rate higher than the average of experimental fragment 
screening, demonstrating the potential of this technique in FBLD against β-lactamases.  In 
addition, molecular docking performed well in predicting fragment binding poses when 
compared to subsequently determined crystal structures.  
	   9	  
Finally, in vitro biochemical assays are available for β-lactamases that allow for the 
biochemical characterization (Ki) of fragments with very weak affinities.   This is in contrast to 
many other classes of targets, where functional biochemical activity is not easily measured for 
weak affinity fragments. Many β-lactam substrates have been developed over the years to study 
β-lactamase activities in the context of bacterial resistance, and these reagents now provide 
convenient UV-absorption based assays for testing fragments (93).  More substrates are being 
developed, such as those for fluorescence-based activity assays (94), and this allows the selection 
of a suitable substrate for a particular β-lactamase and/or the identification of false positive hits 
by using substrates with different fluorophores. The use of molecular docking also reduces by 
orders of magnitude the number of compounds that need to be experimentally tested.  This 
enables biochemical assays to be used for primary experimental testing alongside, or in place of, 
other techniques such as SPR (80).   
 
Class A β-Lactamases 
Clinically, the Class A β-lactamase CTX-M is the most commonly encountered ESBLs 
(14).  This very diverse group of enzymes has evolved enhanced activities against third 
generation cephalosporins such as cefotaxime and ceftazidime.  There are five subgroups of 
CTX-M β-lactamases, CTX-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25, based on 
sequence similarities. The active sites of all these subgroups share high sequence and structural 
conservation, with a slightly enlarged binding site (e.g., Asp240 vs Glu240 in TEM-1) to 
accommodate the bulky side chains of extended spectrum β-lactam antibiotics, as well as 
particular protein residues to enhance substrate binding (e.g., Ser237).   Given the importance of 
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this family of enzymes, it is not surprising that CTX-M has been the focus of the most significant 
FBLD efforts to date on β-lactamase.   
Using CTX-M-9 as a model system, a series of fragment screening and optimization 
experiments have led to the first nM-affinity non-covalent inhibitor against any serine β-
lactamase (Fig. 2,3) (78, 79).  The program DOCK was employed to screen both the fragment 
and lead-like subset of the ZINC small molecule database (92, 95, 96). Out of 70,000 fragment 
compounds, 69 were selected for experimental testing and 10 were shown to be inhibitors (Fig. 
6a). In contrast, no inhibitors were found among the 34 candidates chosen from one million lead-
like compounds.  The failure with screening lead-like compounds is likely due to a combination 
of the inaccuracy of docking methods in general and the more sporadic coverage of chemical 
space by the larger lead-like compounds. Inadequate sampling of conformational space and 
errors in scoring functions may pose a larger challenge for docking lead-like compounds than 
fragments because such problems can be amplified due to the larger number of conformations 
and interactions that need to be calculated for lead-like compounds. Also, as discussed below in 
studies using AmpC as a model system, many inhibitor chemotypes may be available at much 
lower percentages in commercial lead-like databases in comparison to fragment databases, 
increasing the difficulty of identifying these inhibitors in screening lead-like compounds.   
Five crystal structures of CTX-M-9 were determined in complex with fragment inhibitors 
to resolutions of 1.5 Å or better.  Several inhibitors only appeared in the active site with partial 
occupancy, and they overlapped with a phosphate and water molecules usually observed in the 
apo crystal. The value of high-resolution structures for FBLD against β-lactamases is 
demonstrated by details of the ligand electron density permitting the differentiation of the apo 
and complex states of the active site.  These structures also demonstrated the ability of molecular 
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docking to successfully predict ligand binding conformations, which played a significant role in 
subsequent lead optimization efforts.  The crystal structures with fragment inhibitors revealed 
several key binding hot spots (Fig 6b): 1) the subpocket (Ser130, Thr235) that normally harbors 
the C3(4)’-carboxylate group of the β-lactam substrates and that is well complemented by the 
tetrazole ring present in several fragments, 2) the polar side chain of Asn132, which also 
hydrogen bonds with the amide bond in β-lactam compounds, 3) an aromatic/hydrophobic site at 
the base of the active site formed by Tyr105 and, 4) the residues Gly236, Ser237 and Gly238 in 
the b3 strand.  A subsequent search for commercial tetrazole analogs uncovered a 21µM 
inhibitor that served as the template for ensuing fragment-based lead optimization efforts (Fig. 
7).  Interestingly, the 21µM inhibitor was present in the lead-like subset of the ZINC database 
but did not rank especially high in the original docking screen, and therefore was not among the 
34 docking hits initially analyzed.  At this stage, chemical synthesis was employed to explore 
additional functional groups targeting either of two binding hot spots; a hydrophobic site formed 
by Pro167, and the side chain of Asp240.  Compounds targeting each site were identified, and 
these exhibited binding affinities of 1-2 µM(79).  Combining these features in new molecules 
targeting both sites then yielded compounds with sub-µM affinities, including an 89 nM inhibitor 
that reduced the MIC of cefotaxime by 32-64 fold in clinical E. coli isolates expressing CTX-M-
9 (Fig. 7). This early effort with CTX-M suggests FBLD can be a powerful platform for probing 
hot spots in the active sites of other class A β-lactamases.  Due to the high structural 
conservation among CTX-M enzymes, the new tetrazole-based scaffolds are expected to inhibit 
other CTX-M β-lactamases, and some recent unpublished results have confirmed this hypothesis. 
The tetrazole functional group may also be useful in targeting other serine β-lactamases because 
the corresponding protein subpocket is mostly conserved in these enzymes.  Interestingly, as 
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discussed below, a tetrazole functional group has also been shown to be an effective chelator of 
the zinc ion in metallo β-lactamases.   
 
Class C β-Lactamases 
For many years, AmpC Class C β-lactamase has been the subject of novel drug discovery 
efforts and a model system for investigating fragment-based methods.  Overproduction of AmpC 
confers resistance to cefotaxime and other broad-spectrum β-lactam antibiotics (97), yet unlike 
CTX-M and Class A ESBLs, AmpC is resistant to classical β-lactamase inhibitors such as 
clavulanate (98). A recent virtual screening campaign docked a library of 137,639 fragment 
compounds against E. coli AmpC (80).  Forty-eight molecules were selected for experimental 
testing from the top-ranking list and 23 were shown to be inhibitors (Fig. 8a).  The complex 
structures of these fragments, together with those from a previous study, highlighted several 
binding hot spots similar to those revealed by the fragments identified for CTX-M (Fig. 8b): 1) 
the subpocket (Tyr150, Thr316) for the C3(4)’-carboxylate group of the β-lactam substrates,2) 
the polar side chain of Asn152, which serves as a hydrogen bond donor, 3) a hydrophobic shelf 
formed by Tyr150, Leu119, or in some cases Ile291, 4) the residues Gly317, Ala318, and Thr319 
in the b3 strand, including the oxyanion hole formed by the backbone amide groups of the 
catalytic Ser64 and Ala318.The fragment inhibitors also revealed some novel binding hot spots 
such as a distal subpocket surrounding Ser212 and Gly320, and suggested the merging of these 
fragment scaffolds with earlier boronic-acid based covalent inhibitors (Fig. 9) (99-102).  These 
fragment-derived modifications were found to increase binding affinity of the covalent inhibitor 
by more than 20-fold (45).  Subsequent optimization efforts improved the Ki by an additional 25-
fold to 50 pM.  The development of this sub nanomolar inhibitor demonstrates the value of 
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FBLD in modifying and improving existing lead compounds, including those identified through 
traditional screening and medicinal chemistry. The virtual screening study also highlighted the 
ability of molecular docking to accurately predict ligand binding poses.  Four out of the eight 
structures determined showed close resemblance to the docking predictions, with RMSDs (root-
mean-square deviations) ranging from 1.2 to 1.6 Å.  Two additional complex structures showed 
RMSDs of around 2.0 Å.   The remaining two fragments bound to the protein in conformations 
dramatically different from the docking predictions, due to protein flexibility not captured by the 
computational method. 
Studies using AmpC as a model system have also produced important insights into the 
challenges and pitfalls of FBLD methods in general.  Babaoglu et al. deconstructed a known 
lead-like AmpC inhibitor into three fragments and found that the fragments did not adopt the 
same binding conformation as they did as part of the lead compound (103).  In fact, the 
fragments interacted with two new sites in the active site.  However, as the fragments were 
combined and elaborated into larger molecules, the new molecules did assume the same binding 
mode as the original lead-like molecule.  These studies underscore the ability of fragments, 
particularly those with very few functional groups, to assume multiple binding poses.  This work 
thus highlights the value of fragment-based approaches to define multiple binding sub-sites, 
while pointing to potential pitfalls for fragment optimization when structural information about 
binding poses is not available. 
Several fragments identified from docking to AmpC were also among the high-scoring 
fragment hits in the screen against CTX-M.  Moreover, biochemical testing of fragment hits from 
the CTX-M studies revealed that they also inhibit AmpC (Fig. 6).  These results demonstrate that 
the high hit rate associated with fragment screening is attributable to the ability of fragments to 
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form a diversity of binding orientations and interactions.  Despite some similarities between the 
active sites of the two enzymes, the cross-inhibiting fragments did not necessarily bind to the two 
proteins in the same orientation.  Crystal structures of one compound bound by CTX-M and 
AmpC showed that the ligand occupies entirely different subpockets in the two enzymes. 
However, as the crystal structures in both cases capture only the most favorable binding 
conformation, it is possible that there are other alternative conformations that could be similar 
between the two proteins.  Accordingly, it is likely that a shared fragment binding orientation 
could be exploited in the design of elaborated molecules that bind both sites with improved 
affinities.    
The virtual screening experiments against AmpC were also used to investigate the 
chemical space covered by fragments in comparison to lead-like molecules (80).  The 
commercially available fragment databases have approximately 1% of all possible chemical 
scaffolds (<17 non-hydrogen atoms) containing validated fragment inhibitors as substructures. In 
comparison, the available lead-like databases have just 0.0000001% of all compounds (<25 non-
hydrogen atoms) containing these fragments.  Thus, the significantly better chemical space 
coverage by fragments is due both to the far fewer number of chemically possible compounds at 
the fragment level, and to the low specificity of fragment inhibitors as illustrated in these studies.  
 
Class D β-Lactamases 
Although Class D enzymes include several problematic carbapenemases, FBLD against 
this group of enzymes has been scarcely investigated (104).  However, some fragment-size 
molecules, particularly polycarboxylic acids, have been found to bind these proteins and may 
serve as starting points for future development of novel inhibitors. Interestingly, similar 
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fragments that have previously bound to the Class A enzyme BS3 were used to develop lead-like 
inhibitors against the Class D enzyme OXA-10. Specifically, citrate, isocitrate, and aminocitrate 
had been previously discovered with modest affinity against BS3, with Ki values of 490 µM, 
2200 µM, and 250 µM respectively (105).  Using these fragments as starting points, Beck et al. 
were able to develop a series of lead-like derivatives (Fig. 10a).  When tested against a wide 
range of β-lactamases, several of these derivatives showed binding affinity against OXA-10 in 
the low µM range. The close similarities between the various polycarboxylate chemotypes 
suggest their ability to target both Class A and D enzymes (Fig. 10b) (106, 107). 
 
Class B β-Lactamases 
Metallo β-lactamases have recently received much attention due to the emergence of 
NDM-1 and several other enzymes in Gram-negative pathogens(108).  The broad substrate 
spectrum of these β-lactamases is of great concern in the medical community, and consequently 
metallo β-lactamases have been the subject of many drug discovery efforts in recent years (93, 
109).  Although HTS has proved more effective for metallo β-lactamases than serine β-
lactamases, FBLD remains a viable and underexploited alternative approach to uncover novel 
chemotypes for metallo-enzymes.   
Using a chromogenic substrate CENTA, a 500-compound fragment library from 
Maybridge was screened against Pseudomonas aeruginosa IMP-1 β-lactamase (81).  Ten 
inhibitors were identified (Fig. 11a).  Most of these compounds exhibited mixed competitive and 
uncompetitive inhibition, and molecular docking was used to understand both inhibition 
mechanisms.  One of these compounds functioned mainly as a competitive inhibitor and served 
as the starting point of a lead-optimization effort (Fig. 12) (82).  This resulted in a modest 
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improvement of ~10 fold in the IC50 of inhibitors of the same chemotype.  Interestingly, many 
precursors for chemical synthesis also showed activity against IMP-1 and they were subjected to 
further derivatization. These experiments led to an inhibitor with a Ki of 11 µM. 
A docking screen of the fragment set in ZINC against a metallo β-lactamase from Bacteroides 
fragilis uncovered five validated inhibitors among the 15 compounds selected for testing from 
the 50 highest-scoring hits (Fig. 11b) (110).  In addition to the very impressive enrichment rate 
of true inhibitors in the high-ranking molecules, these inhibitors displayed Ki values ranging 
from 120 µM to 2 µM, significantly better than the more typical high µM to low mM affinities 
observed for the fragment inhibitors against serine β-lactamases.  This result highlights the 
general ability of metal centers in these enzymes to form strong interactions with specific 
functional groups (e.g. sulfhydryl) as well as the relative abundance of such moieties in existing 
small molecule databases.  The selectivity exhibited by such inhibitors for metallo β-lactamases 
over other metallo-enzymes is likely to be an important factor in the further development of such 
inhibitors if previous experience with other drug targets (e.g. histone deacetylases (HDACs), 
matrix metalloproteinases (MMPs)) is any guide.  Many additional fragment-sized inhibitors 
have been identified from other screening assays not necessarily involving fragment-based 
approaches (Fig. 11c, compounds: 1 (111), 2 (112), 3 (113), 4 (114, 115), 5 (116), 6 (82), 7 
(117), 8 (118), 9 (119), 10 (69), 11 (120, 121), 12 (122), 13 (123, 124), 14 (125), 15 (81), 16 
(119), 17 (126), 18 (127)).  They cover a diverse range of chemotypes such as compounds 
containing thiol (114) (including mercaptoacetic acids (111, 113, 128) and 
mercaptophosphonates (118)) and dicarboxylate groups (including those with heterocyclic rings 
(119)).  Many of these small compounds were identified by traditional screening at much lower 
concentrations than normally employed for fragment testing.  This again reflects the intrinsic 
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affinity of metal centers for metal-chelating functionality.  In addition to the zinc ions, these 
fragment and previously-identified larger inhibitors have revealed other binding hot spots such as 
the hydrophobic residues on a flexible loop that closes down upon substrate binding as well as a 
lysine/serine residue that anchors carboxylate groups from substrates/inhibitors.  Some of the 
fragment inhibitors have already been incorporated into larger lead-like molecules, providing 
good starting scaffolds for future optimization efforts. The different binding modes of D-
captopril (Fig. 13c, 2) in complex with BlaB subclass B1 (112), CphA subclass B2 (114), and 
FEZ-1 subclass B3 metallo β-lactamase (129) again demonstrate the ability of fragment 
inhibitors to adapt to the particular binding environment of a target protein (Fig. 13a-b) (112, 
130).   Comparing the D-captopril-BlaB structure with another complex structure of IMP-1 also 
suggests that functional groups from D-captopril can be fused with the mercaptocarboxylate 
inhibitor of IMP-1, underscoring the utility of fragment compounds in probing binding hot spots 
(Fig. 13c) (75, 112). 
 
Fragment-Based Lead Discovery Perspective 
In the past several years fragment-based approaches have been successfully applied to 
identify novel inhibitors for both serine and metallo β-lactamases.  The strength of FBLD lies in 
its ability to effectively probe protein binding hot spots and efficiently identify fragment 
compounds complementing these subpockets.  When structural information is also obtained, the 
elaboration of weak binding fragments into more potent lead compounds can occur rapidly, with 
modest synthetic chemistry resources. As still more β-lactamase fragments are identified and 
characterized, the specific molecular recognition properties and ‘druggability’ of the various sub-
sites will become better understood. New fragments for β-lactamases are likely to originate both 
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from de novo screening as detailed herein, and from the deconstruction of existing inhibitors 
identified through traditional non-fragment based approaches. Most importantly, testing these 
various fragments and leads across classes of β-lactamases and their mutants will reveal which 
hot spots are best conserved across enzymes, and might therefore be employed in developing 
expanded spectrum inhibitors.  From the early efforts detailed herein, it is already clear that 
viable inhibitors of β-lactamases can be drawn from a much wider swath of chemical space than 
has been previously appreciated.  Of course, much more work will be required to advance these 
new leads towards molecules that can be deployed clinically to counter bacterial resistance in 
Gram-negative pathogens.  
 
Summary 
 The β-lactamases hydrolyze β-lactam antibiotics including pencillins, cephalosporins, 
and carbapenems, representing one of the primary resistance mechanisms used by Gram-negative 
bacterial pathogens against these pathogens.  Four classes of β-lactamases are commonly found 
in resistant bacteria.  Class A, C, and D use a catalytic serine to catalyze the reaction, whereas 
Class B are metallo enzymes.  High-throughput screening has been ineffective in identifying 
novel inhibitor chemotypes against serine β-lactamases, but has been used with some success in 
inhibitor discovery against metallo- β-lactamases.  Fragment-based approaches use low 
molecular weight compounds (<250 Dalton) to probe small molecule binding sites in proteins 
and enzymes.  Their small size allows for better coverage of chemical space than larger drug-like 
molecules.  Fragments can be converted into more potent compounds by employing fragment 
linking or growing strategies, which are facilitated when fragments are structurally characterized. 
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Fig 1. β-lactam Antibiotics.  Compounds representing the main classes of  
β-lactam antibiotics from the 1st generation penicillins to the 3rd generation 
cephalosporins.   	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Fig 2.  CTX-M-9 Active Site.  The active site of CTX-M-9 is shown.  Active site 
side chain residues are represented as stick models.  The water molecule is 
represented as a red sphere.  Hydrogen bonds are shown as black dashed lines.   
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Fig 3. Reaction Pathway for Class A β-lactamases.  The hydrolysis reaction catalyzed by CTX-M 
proceeds through a precovalent complex, a high-energy tetrahedral acylation intermediate, a low-energy 
acyl-enzyme complex, a high-energy tetrahedral deacylation intermediate after attack via a catalytic 
water, and lastly, the hydrolyzed β-lactam ring product which is released from the enzyme complex.  
Reprinted with permission from (19), The Deacylation Mechanism of AmpC β-Lactamase at Ultrahigh 
Resolution, Chen et al, 2006 American Chemical Society (see Appendix 2). 	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Fig 4.  Proposed Acylation Mechanisms of Class A β-lactamases. (a) Possible 
mechanism which designates Lys73 as the general base. (b) Possible acylation 
mechanism in which Glu166 acts as the general base via the catalytic water 
(wat1).  Hydrogen bonds are represented as blue dashed lines and the purple 
arrows represent the electron transfer.  Reprinted with permission from (17) Chen 
et al., The Acylation Mechanism of CTX-M β-Lactamase at 0.88 Å Resolution, 
2007 American Chemical Society (see Appendix 3). 	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Figure 5. β-Lactam Antibiotics and β -Lactamase Inhibitors.  Compounds 
represent the main classes of β-lactam antibiotics in clinical use such as penicillins, 
cephalosporins, including third-generation such as ceftazidime, and carbapenems.  
Clavulanate is a class A β-lactamase inhibitor while avibactam and RPX7009 are 
broad-spectrum covalent inhibitors in clinical trials.  	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Figure 6.  Fragments Targeting Class A β-lactamase.  (a) Anionic fragments 
identified by virtual screening against CTX-M Class A β-lactamase (75).  Many of 
these fragments also demonstrated activity against the class C enzyme AmpC.   (b) X-
ray crystallographic structures of fragments in complex with CTX-M β-lactamase. 
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Figure 7.  Fragment-Based Drug Design Against Class A β -lactamase. 
Schematic showing the fragment-based approach to develop a lead-like inhibitor 
against CTX-M-9 β-lactamase. 
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Figure 9.  Fragment-Based Drug Design Against Class C β-lactamase.  
Schematic showing the fragment merging approach used to develop a lead-like 
inhibitor against AmpC β-lactamase [42,77].   
 
Ki	  	  3.0mM	  	   Ki	  	  70nM	  	  
Ki	  	  1.2nM	  	  
	   28	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
NH2
O
O O
O O
Ph
Ph
Ph
O H
N
O
O O
O O
O
O
Ph
Ph
Ph
Ph
O
OH
HO
O OH
HO O
O
NH2
HO
O OH
HO O
Figure 10.  Fragment-Based Drug Design Against Class D β-lactamase.  (a) Schematic showing 
the fragment-based approach to develop a lead-like inhibitor against OXA-10, a class D β-lactamase.  
Initially, the fragments were identified inhibiting the class A β-lactamase BS3.  Lead-like 
optimization of these fragments allowed for the identification of compounds inhibiting OXA-10[90]. 
(b) X-ray crystal structures of class D, OXA-46 in complex with tartaric acid (PDB ID 3IF6), and 
class A BS3 in complex with aminocitrate (PDB ID 3B3X), showing polycarboxylic acid molecules 
binding to the active sites of both proteins. 
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Figure 12.  Fragment-based Lead Discovery for a Class B β-lactamase. Schematic showing 
the fragment-based approach to develop a lead-like inhibitor against IMP-1, a metallo β-
lactamase [78,79]. 
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Figure 13.  Fragment Binding Hot Spots for Class B β-lactamases. (a) X-ray crystallographic structure of 
the inhibitor D-captopril in complex with BlaB metallo β-lactamase (PDB ID 1M2X).  (b) X-ray 
crystallographic structure of D-captopril in complex with CphA metallo β-lactamase (PDB ID 2QDS).   (c) 
The binding pose of D-captopril (yellow) from the BlaB complex structure  (enzyme structure not shown, 
PDB ID 1M2X) is superimposed on the complex structure of IMP-1 with  MCI (cyan),  a 
mercaptocarboxylate inhibitor (PDB ID 1DD6).  The IMP-1 residues are in green.   The zinc ions are in 
grey.   
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Chapter 2 
 
Structure-Based Design of Inhibitors against CTX-M Class A β-Lactamase 
 
Note to Reader 
 Portions of this chapter have been previously published and reprinted with permission 
from (79) (Nichols et al., 2012 J Med Chem) (see Appendix 4).   
 
Overview 
The emergence of CTX-M Class-A extended-spectrum β-lactamases, which confer 
resistance to second and third-generation cephalosporins, poses a serious health threat to the 
public.   Through a fragment-based screening approach, we recently identified 3-fluoro-N-[3-
(1H-tetrazol-5-yl)-phenyl]-benzamide, a novel non-covalent tetrazole-containing inhibitor of 
CTX-M.  In the current study, we applied structure-based design to improve the potency of the 
original tetrazole lead (Ki = 21 µM) more than 200-fold via small, targeted structural 
modifications.  Specifically, a series of compounds were synthesized to probe two potential 
binding hotspots – a hydrophobic shelf formed by Pro167 and a polar site anchored by Asp240.  
Initially we sought to target these two hotspots independently, and this effort produced new 
analogs with potencies that were improved by about 10-fold (Ki = 1-2 µM).  Subsequent designs 
intended to contact both hotspots produced analogs with sub-micromolar potencies, including 6-
trifluoromethyl-3H-benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide, 
which had a Ki value of 89 nM and reduced the MIC of cefotaxime by 64-fold in CTX-M-9 
expressing Escherichia coli.   The in vitro potency gains were accompanied by improvements in 
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ligand efficiency (from 0.31 to 0.39) and LipE (from 1.37 to 3.86).  These new analogs represent 
the first nM-affinity non-covalent inhibitors of a Class A β-lactamase.  Their complex structures, 
determined at ~1.2-1.4 Å, provide valuable information about ligand binding to CTX-M that will 
aid future inhibitor design. 
 
Introduction 
 β-Lactam compounds, such as penicillins, are the most widely used antibiotics due to 
their effective inhibition of the transpeptidases required for bacterial cell wall synthesis.(2, 9-11) 
β-Lactamases catalyze β-lactam hydrolysis and are primary mediators of bacterial resistance to 
these compounds (26, 131, 132).  There are four β-lactamase families, Classes A to D, among 
which Classes A and C are the most commonly observed in the clinic (12, 13).  CTX-M is a new 
group of Class A β-lactamases that is particularly effective against the extended spectrum β-
lactam antibiotics such as cefotaxime (14-18), which itself was developed to counter bacterial 
resistance to first-generation penicillins and cephalosporins.  The widespread emergence of 
extended spectrum beta-lactamase (ESBL) such as CTX-M will continue to limit treatment 
options for bacterial infections.  Since its discovery in the 1990s (14), CTX-M has become the 
most frequently observed ESBL in many regions of the world.  
The use of a β-lactamase inhibitor in combination with a β-lactam antibiotic is a well-
established strategy to counter resistance (33). Existing β-lactamase inhibitors (e.g. clavulanic 
acid) generally contain a β-lactam ring, making them susceptible to resistance stemming from 
up-regulation of β-lactamase production, selection for new β-lactamases, and other mechanisms 
evolved over millions of years’ of chemical warfare between bacteria and β-lactam producing 
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microorganisms (35, 37, 133, 134). In principle, these problems can be overcome by developing 
structurally novel (non-β-lactam) inhibitors of β-lactamases (101, 135-138). 
We recently described our application of fragment-based molecular docking to identify a 
new class of non-covalent inhibitors of CTX-M β-lactamase (78, 87).  The fragment-based 
approach allowed us to overcome the limited chemical diversity of lead/drug-sized compound 
libraries, which presents a particularly challenging problem for antibiotic discovery.  This is due 
to the starkly different chemical features of antibiotics when compared to drugs targeting human 
proteins such as GPCRs, towards which most HTS screening libraries are inherently biased (51, 
139, 140). Thus, our virtual screening of fragment libraries led to the discovery of a tetrazole-
based inhibitor chemotype, represented by compound 1, at the time the highest affinity (Ki = 21 
µM) non-covalent inhibitor of any Class A β-lactamase (Fig. 14, Table 1).  The tetrazole-based 
chemotype appealed to us for several reasons.  First, the tetrazole group has excellent shape and 
electrostatic complementarity with the active site subpocket of CTX-M that usually binds the 
C(3)4’ carboxylate of traditional β-lactam antibiotics (Fig. 14).  Second, the tetrazole ring is a 
well-known binding bioisostere for carboxylate groups that often possesses more favorable 
pharmacokinetic properties.  
Close examination of the complex crystal structure with compound 1 revealed two 
potential binding hot spots that might be exploited to improve affinity (Fig. 14).  The first is a 
relatively non-polar binding surface surrounding Pro167, while the second site, anchored by 
Asp240, suggested the possibility of introducing a favorable electrostatic interaction. The design 
and synthesis of compounds that focused on interacting with these binding hotspots has resulted 
in several novel high affinity non-covalent inhibitors.  The binding of many new inhibitors to the 
CTX-M active site was further investigated using X-ray crystallography.  Targeting both hot 
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spots with small substituents allowed us to identify more ligand-efficient inhibitors, including the 
highest affinity (Ki = 89 nM) non-covalent inhibitor of a Class A β-lactamase reported to date.   
 
Results 
Structure-Based Design 
 Compound 1, and other less potent inhibitors were identified by a molecular docking 
screen of the ZINC lead-like database using the program DOCK (19, 78, 92, 141).  In the 
complex crystal structure of 1 with CTX-M, the fluoro-benzene ring is in close proximity to 
Asp240 and the binding surface surrounding Pro167.  Two carbon atoms on the fluoro-benzene 
ring are in vdw contact (3.43 Å) with the Oδ1 atom of Asp240.  Although there are favorable 
electrostatic interactions between the ring hydrogen atoms of 1 and Asp240 Oδ1, we 
hypothesized that a hydrogen bonding interaction or a salt bridge to Asp240 in a modified ligand 
would greatly enhance binding affinity. In a previously determined complex structure with a 
boronic acid inhibitor bearing a ceftazidime side chain (PDB ID 1YLY) (17), Asp240 has been 
observed to form such a hydrogen bond with the distal amine group of the ligand, which may 
partially account for the improved β-lactamase activity of CTX-M against ceftazidime.  
Meanwhile, the fluorine atom of compound 1 is 4-5 Å away from a cluster of protein carbon 
atoms including Pro167Cβ, Pro167Cγ, Pro167C, Thr168Cα and Thr171Cγ, suggesting that more 
favorable vdw contacts and hydrophobic interactions could be formed between this site and 
analogs modified at the three position of the aryl ring.   Hence, based on these observations from 
the complex structure of 1, two series of analogs independently targeting each of the two 
potential binding hot spots were designed, docked and synthesized.  
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Synthesis 
 The simple achiral structure of 1 is an attractive feature of this chemotype compared to 
traditional β-lactamase inhibitors.  Designed analogs that docked well to CTX-M 
computationally were synthesized in 1-3 synthetic steps, or in some cases could be purchased 
commercially.  Thus, reaction of commercially available 3-(1H-tetrazol-5-yl)aniline with various 
commercial or synthesized carboxylic acids or acid chlorides afforded the final analogs.  Our 
initial designs focused exclusively on the 3-fluoro aryl ring of 1 as this moiety is in proximity to 
both of the putative binding hot spots we sought to target.   The aryl tetrazole moiety of 1 
appears to be highly complementary to its binding site already and was thus viewed as a 
structural anchor that would be unlikely to bind much differently in the new analogs.  This 
prediction was borne out when complex structures of new analogs were solved, as detailed later.   
 
Enzymology and Binding Affinities 
 To investigate the effectiveness of the new analogs, we employed CTX-M-9 and a UV-
absorbance based biochemical assay to obtain binding affinities.  A series of analogs with 
modifications at the three position were evaluated with the expectation that these compounds 
would form more favorable non-polar contacts with Pro167 (Table 1).  Compounds 2-11 possess 
3-substituents of roughly increasing size and with generally lipophilic character, though not 
exclusively so.  Interestingly, all of these modified analogs proved superior to 1 in terms of Ki, 
but the most ligand-efficient analogs were those possessing spheroid hydrophobes (e.g., Me, Br, 
CF3).  The highest affinity compound from the series targeting Pro167 was compound 10, the 3-
trifluoromethyl variant, with a Ki of 2.4 µM (Table 1).   Analogs 6-8, bearing less hydrophobic 
and non-spheroid substituents, had similar ligand efficiency as 1 but superior LipE values (1.37 
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for 1 vs. 2.51 for 7).  The parameter LipE (142) (defined as logKi – clogP)(143) provides a 
measure of binding affinity improvement achieved while retaining favorable physiochemical 
properties.  A surprising result was that even large substituents (2-pyrimidyl, compound 11) 
could be tolerated at the 3-position, although ligand efficiency suffers.  A complex crystal 
structure of 11 confirmed a similar binding pose as 1 (see below), so the reduced ligand 
efficiency of this analog perhaps reflects a steric clash and/or unfavorable desolvation energy 
associated with the burial of a pyrimidine ring nitrogen atom.  To target the second hotspot 
comprising the area around Asp240, we designed analogs bearing hydrogen bond donors and/or 
charged side chains at various positions on the aryl ring.  These various designs were docked to 
CTX-M and some of the best-scoring analogs were synthesized and tested in the biochemical 
assay (Table 2).  Our attempt to form a salt bridge to Asp240 by the introduction of a basic 
dimethylamino side chain (compound 12) was unsuccessful, the analog possessing only modest 
affinity (Ki = 76 µM).  The regioisomeric aryl nitriles 13 and 14 had very different affinities, 
with meta-substitution as in 14 preferred (Ki = 7.2 µM).  By far the most interesting analogs 
from this series (Ki ~ 1 µM) were the heterocyclic analogs 16-18, each of which possesses a 
potential hydrogen bond donor in a position (pseudo meta or para) predicted by docking to be in 
close proximity to Asp240. Moreover, compounds 16-18 exhibited improved ligand efficiency 
(0.34 – 0.35) and LipE values (2.59 – 3.58) as compared to 1 (0.30 and 1.37). 
 From these initial two libraries, we concluded that the independent targeting of each 
binding hotspot (Asp240 and Pro167) could indeed be leveraged to produce more potent and 
ligand-efficient inhibitors.  As described below, the design principles and predicted binding 
poses of these initial analogs were validated by the solution of complex crystal structures for 
representative examples.  Having identified more favorable binding elements for both hotspots, 
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the logical next step was to combine these to produce inhibitors that targeted both sites 
simultaneously (Table 3).  Indeed, the combination of a benzimidazole ring as in 16 with a 
trifluoromethyl substituent as in 10, afforded analog 19, the most potent analog yet identified (Ki 
= 89 nM; L.E. = 0.36; LipE = 3.86).  We expected that the benzimidazole ring in 19 might 
contribute an important hydrogen bond to Asp240 and therefore explored whether simple 
hydroxyl or amino substituents in this position could function similarly (analogs 20-22).  These 
analogs were indeed more potent than the direct comparators 4 and 10 which lack a hydrogen 
bond donor, but 20-22 were not as potent as 19.  As detailed later, the solution of a complex 
structure of benzimidazole analog 16 revealed additional contacts that may explain the improved 
potency of benzimidazole 19 as compared to 20 and 22.  Unexpectedly, the fluoro benzimidazole 
analog 23 was only equipotent to des-fluoro comparator 16, the fluoro substituent apparently not 
providing any additional affinity via putative interaction with Pro167.  Perhaps tighter 
association of the benzimidazole ring with Asp240 draws the ligand slightly away from Pro167, 
thus requiring a larger substituent (such as trifluoromethyl in 19) to productively contact Pro167.  
 
X-ray Crystallographic Structure Determination 
The structural details of the interactions between CTX-M-9 and several of the new 
analogs were investigated in order to gain an understanding of the molecular basis for the 
binding affinity improvement and to facilitate future inhibitor development.  Complex crystal 
structures with CTX-M-9 were determined to a resolution in the range of 1.2-1.4 Å, where the 
ligand binding pose can be determined unambiguously.  In all of these structures, the inhibitor 
adopts a single pose, as shown by the unbiased Fo-Fc electron densities calculated prior to the 
fitting of the ligand.   
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Figure 2 shows the X-ray crystal structures of compounds 4, 10, and 11 in the active site 
of CTX-M-9; these compounds were designed to make significant non-polar interactions with 
Pro167.  The size increase in the bulkier side substituents such as trifluoromethyl is 
demonstrated in their larger electron density volumes, compared with that of the fluorine atom in 
1.  In the larger sense, the atoms of the new ligands make similar contacts with the surrounding 
active site atoms, as does 1.  For instance, compounds 4, 10, and 11 (Fig. 15 a-c) all form 
hydrogen bonds between the tetrazole ring and Thr235, Ser237, and Ser130 from the protein, 
which is similar to compound 1 (Fig. 14, Table 1).   They also share the characteristic water-
mediated interaction between the amide linkage and Ser237, as well as two hydrogen bonds with 
Asn132 or Asn104.  The contacts between the distal benzene ring and Asp240, as observed in 
compound 1, are maintained in compounds 4 and 10, with two ring carbon atoms in vdw contact 
and approximately 3.2-3.3 Å away from the Oδ1 atom of Asp240. The favorable contacts 
between Pro167 and the functional groups on 4 and 10 are evident.  The bromine atom on the 
ring structure of 4 is 4-5 Å away from the cluster of protein carbon atoms including Pro167Cβ, 
Pro167Cγ, Pro167C, Thr168Cα, and Thr171Cγ.   Likewise, the three branched fluorine atoms of 
compound 10 are in close vdw contact with these protein carbon atoms, which are approximately 
3.4-3.8 Å away.  The binding of compound 11, on the other hand, differs slightly from 
compounds 1, 4 and 10 in these regions (Fig. 15c).   The pyrimidine ring forms a water-mediated 
interaction with Asp240 and induces Asp240 to adopt a new conformation (Fig. 15).  This water-
mediated contact exists in the complex structure with only partial occupancy, as suggested by the 
relatively weak electron density of the water (2 σ) and the presence of two Asp240 
conformations, including the one previously observed in apo and other complex structures.  
There is vdw contact observed between the carbon atoms of the pyrimidine ring in 11 and 
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Pro167Cγ, Thr168Cγ, Thr171Cγ, which are 3.3-3.6 Å away.  Despite the water-mediated 
hydrogen bond and vdw contacts between the ring carbon atoms and Pro167 and Thr168, the 
affinity of compound 11 is less than that of 4 or 10; this may be due to unfavorable burial of a 
polar pyrimidine ring nitrogen atom and electrostatic repulsion between this nitrogen and 
Pro167O.   Additionally, the vdw contacts described above may be slightly too close for the 
optimal carbon-carbon distance in vdw interaction (~ 4 Å) and thus suggest a possible minor 
steric clash. 
 Crystal structures were also obtained for compounds designed to establish polar 
interactions with Asp240, including compounds 12, 16, and 18.   Again, the core structure of 
these compounds, including the tetrazole ring and the amide bond, establishes contacts with 
Ser130, Thr235, Ser237, Asn104 and Asn132, similar to compound 1 (Fig. 16a-c).     Both 
compounds 16 and 18 form a direct hydrogen bond with Asp240 as designed.  In addition, 
compound 16 has a favorable contact between N-1/C-2/N-3 of the benzimidazole ring and the 
main chain atoms around Gly238, while compound 18 establishes more vdw interactions with 
Pro167 and Thr168.  The second ring nitrogen (N-3) in benzimidazole 16, which is a carbon in 
indole 15, appears to form a water-mediated hydrogen bonding contact with Ser237 (Fig. 
16b).  However, the electron density for the water molecule contacting N-3 in 16 is weaker (2.4 
σ) than other structural waters in the active site, suggesting that this water-mediated interaction 
is relatively unstable and may not contribute to binding affinity significantly.  The modest 
additional affinity of compound 16, in comparison to 15, may instead originate from an 
intramolecular hydrogen bond between N-3 and the proximal amide N-H, an interaction that 
would stabilize the conformation conducive to hydrogen bond formation with Asp240.  
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 Figure 16c shows the discrepancy between the designed interaction of compound 12 with 
Asp240 (in cyan) and its actual interactions observed in the crystal structure (in yellow).  
Initially, we designed compound 12 to form a salt bridge with Asp240.  However, the X-ray 
crystal structure reveals the actual binding pose in which a water-mediated hydrogen bond is 
formed between the positively charged side chain and Asp240.  The new side chain is cradled in 
the small pocket surrounding Pro167, once again underscoring the potential of this binding 
surface in establishing new interactions with future inhibitors. 
 
Antimicrobial Activity 
 The activity of compound 19 was investigated in clinical bacterial isolates that exhibit 
high levels of resistance against third-generation cephalosporins (e.g., cefotaxime) via expression 
of CTX-M β-lactamases. When the compound was administrated alone in a disk diffusion assay 
it had little or no detectable effect on bacteria growth, as expected (Fig. 17). However, in 
combination with cefotaxime the compound produced a large inhibition halo surrounding the 
disk. The size of the inhibition zone showed improved inhibition of bacterial growth compared to 
cefotaxime alone and increased with the concentration of the compound. This dose-responsive 
inhibition of bacterial growth revealed clear synergy between cefotaxime and 19.  
Antimicrobial activity was investigated quantitatively to determine the minimum inhibitory 
concentrations (MICs) of the β-lactam/inhibitor combination necessary to inhibit bacterial 
growth. The MICs of cefotaxime alone against the two Escherichia coli strains, expressing CTX-
M-14 and CTX-M-9 respectively, corresponded to a high level of resistance (MICs, 32 and 64 
µg/mL) according to Clinical and Laboratory Standards Institute (CLSI) standards (144). 
Compound 19 had no measurable antibiotic activity when used alone (MIC, ≥ 64µg/mL). In 
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combination with cefotaxime, compound 19 improved MIC values by 64-fold and restored 
susceptibility to cefotaxime in these resistant bacterial strains (MICs, 0.5 and 1 µg/mL). These 
results provide evidence that compound 19 is able to cross bacterial outer membrane to access its 
intended target.  
 
Discussion 
 The identification of novel non-covalent inhibitors of class A β-lactamases is a promising 
approach to maintain the effectiveness of β-lactam antibiotics.  The purpose of this initial study 
was to rapidly identify regions of the active site that could be more productively engaged with 
designed ligands, thus enabling further optimization of tetrazole-based inhibitors of CTX-M β-
lactamase.  The targeted introduction of new functional groups in the distal ring of 1 succeeded 
in producing improved analogs that make both non-polar and polar contacts with CTX-M β-
lactamase, improving affinity ~200-fold whilst retaining good lead-like properties (reflected in 
notably improved LipE values).  The results confirm the importance of Pro167 and Asp240 as 
binding hotspots in CTX-M β-lactamase and demonstrate the tractability of this novel inhibitor 
chemotype. 
Both Pro167 and Asp240 have been observed to interact with β-lactam substrates or 
covalent inhibitors in complex structures with CTX-M-9.  In a recent crystal structure of CTX-
M-9 S70G mutant and cefotaxime (PDB ID 3HLW)(18), the amino group on the aminothiazole 
ring of cefotaxime forms a hydrogen bond with Asp240 while the methoxyimino group nestles 
comfortably in the subpocket around Pro167.  Compared with the apo structure, such interactions 
cause small shifts in atom positions for residues in this area (e.g., ~0.5 Å for Asp240Cα); a 
conformational change not observed in complex structures with smaller substrates such as 
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benzylpenicillin.  Similar hydrogen bonds with Asp240 have also been found in previous 
complex structures with boronic acid inhibitors(17, 18).  Additionally, Pro167 and Asp240 are 
conserved in other CTX-M type enzymes such as Toho-1(145-147).  In the acyl-enzyme 
complex structure of Toho-1 Glu166A mutant with cefotaxime (PDB ID, 1IYO) (147), the 
aminothiazole ring makes both a direct and a water-mediated hydrogen bond with Asp240 while 
establishing vdw interactions with Pro167.  Together with our studies described herein, these 
observations suggest both Asp240 and Pro167 are binding hot spots useful for inhibitor design 
against CTX-M β-lactamases.   
Even more significantly, it is possible to consider targeting similar hot spots in other 
Class A β-lactamases.  In narrow-spectrum β-lactamases, such as TEM-1 and SHV-2, residue 
240 is a glutamate.  Although it has been hypothesized that the substitution of Glu240 for Asp 
may enlarge the active site and allow ESBLs, such as CTX-M, to accommodate the bulkier side 
chains of cefotaxime and other third-generation cephalosporins, both Glu240 and Asp240 present 
similar features in the protein binding pocket, including the net negative charge and the nearly 
identical positioning of one oxygen atom from the carboxylate group.   Comparing the complex 
structures between a ceftazidime-like boronic acid inhibitor and CTX-M-9 (PDB ID, 1YLY), to 
that of the same compound with TEM-1 (PDB ID 1M40) shows that the aminothiazole ring of 
the inhibitor is placed in similar positions and forms a hydrogen bond with residue 240 in both 
structures(17, 148).  Additionally, comparing the affinity of compound 19 with those of 
compounds 21 and 22 suggests that interactions with the main chain atoms around Gly238, the 
residue immediately preceding Asp240 (note the numbering gap due to convention), may also 
contribute significantly to binding.  Gly238 is highly conserved in CTX-M, TEM and SHV 
enzymes.   Meanwhile, the non-polar binding surface around residue 167 is also largely 
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conserved in these β-lactamases.  Like CTX-M, TEM-1 has a proline in this position.  Although 
it is replaced by a threonine in SHV enzymes, most of the carbon atoms, like Cα, Cβ atoms of 
residues 167 and 168, are in similar positions and thus form a binding subpocket with features 
comparable to that in CTX-M, albeit with some new features such as Thr167Oγ.  In the crystal 
structure between cefoperazone and SHV-1, the carbon atoms of the compound’s piperazine ring 
are in vdw contacts with the Cβ and C atoms of Thr167(149). 
In addition to revealing the importance of Pro167 and Asp240 in ligand binding, the rapid 
evolution of compound 1 into nanomolar inhibitors like 19 demonstrates the tractability of the 
tetrazole chemotype as a lead scaffold.  The five-member tetrazole ring displays both good shape 
and electrostatic complementarity with a subpocket usually occupied by the C(3)4’ carboxylate 
group of β-lactam compounds, forming three hydrogen bonds with Ser130, Thr235 and Ser237 
while being stacked against the peptide bond between Thr235 and Gly236.  Several key features 
of this binding subpocket are also present in the active site of AmpC Class C β-lactamase.  For 
example, Thr235 and Gly236 are conserved in AmpC (Thr316 and Gly317).  Tyr150, a key 
catalytic residue in AmpC, places its hydroxyl group in a position similar to that of Ser130 in 
CTX-M.  Other common features shared by the active sites of Class A and C enzymes may 
further allow the design of inhibitors with broader spectrums.  For instance, existing covalent 
inhibitors against both classes of enzymes almost invariantly place an oxygen atom in the 
oxyanion hole formed by two backbone amide groups.  A water molecule occupies the oxyanion 
hole in the complex structures of our tetrazole-based inhibitors.  The identification of tetrazole-
based inhibitors that favorably displace this water molecule may improve binding affinity and 
expand the utility of this chemotype to target a wider range of β-lactamases.     
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Conclusions 
Structurally guided optimization of a novel-class of CTX-M β-lactamase inhibitors has 
confirmed two binding hotspots that can be targeted to produce high affinity inhibitors.  
Importantly, these hotspots are shared by other therapeutically important groups of β-lactamases, 
suggesting the potential for tetrazole-class inhibitors with an expanded spectrum of β-lactamase 
activity.  More generally, the approach we have employed to identify and optimize novel non-
covalent inhibitors of CTX-M can be applied to develop novel inhibitors of other important β-
lactamases.  The nanomolar potency of 19 distinguishes this compound as the highest-affinity 
non-covalent inhibitor yet identified for a Class A β-lactamase.  Its antimicrobial activity also 
demonstrates the possible utility of the tetrazole scaffold in countering bacterial resistance. 
Current efforts are focused on further elaborating the tetrazole chemotype, with the goal of 
producing a novel class of compounds effective against a wide range of clinically relevant β-
lactamases.    
 
Experimental Methods 
Compound Docking 
 Molecular docking was used to evaluate newly designed compounds or existing ones 
from the ZINC small-molecule database with the program DOCK 3.5.4.   The fragment (<250 
amu) and lead-like databases (>250 amu) of ZINC were used to dock into the active site of the 
previously determined 0.88 Å CTX-M9 crystal structure solved (PDB ID 2P74).   The conserved 
catalytic water and structural water interacting with previously inhibitors in complex was left in 
the protein active site, however, all remaining ions and water molecules were removed.  The 
hydrogen atom positions of polar groups for Ser237,  Ser235, Ser130, and Ser70, catalytic water, 
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and the structural water were positioned according to the previously solved 0.88 Å.  The 
matching sphere set used for placing ligands in the active site pocket was produced by using the 
previously solved X-ray crystal structure of CTX-M9 in complex with compound 1.    The 
potential energy scoring grids included a volume grid, a van der Waals grid, and an electrostatic 
interaction grid, based on DISTMAP, CHEMGRID, and DelPhi respectively, along with a 
desolvation grid calculation.  The net charges of the residues in the protein were not changed.  
The partial charges were changed for the Oγ, HOγ, HN, and O atoms of Ser70, Ser130, Ser237, 
and the Oδ1 and HNδ2 atoms of Asn104 and Asn132.   The compounds chosen among the 
screens were those that ranked among the top 500 or in some cases the top 1000 compounds for 
assay testing.  Additional screens were developed as compound testing progressed, focusing on 
various hot spots of the CTX-M9 active site, and choosing compounds which appeared visually 
favorable and also contained negatively charged chemotypes such as the tetrazole-based 
moieties.  
 
 Synthesis 
 Note to Reader 
 This portion of the experimental methods section for this chapter was performed by the 
Renslo et al laboratory, previously published, and have been reproduced with permission from 
(79) (Nichols et al., 2012 American Chemical Society) (see Appendix 4).   
 1H NMR spectra were recorded on a Varian INOVA-400 400 MHz spectrometer. 
Chemical shifts are reported in δ units (ppm) relative to TMS as an internal standard. Coupling 
constants (J) are reported in hertz (Hz).  The known compounds 1, 2, 3, 4, 6, 8, 10 and 13(150) 
were prepared according the the general procedures and/or were obtained from commercial 
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sources (Ryan Scientific, TimTec).   All other reagents and solvents were purchased from 
Aldrich Chemical, Acros Organics, Enamine, Alfa Aesar, Apollo Scientific and used as received.   
Air and/or moisture sensitive reactions were carried out under an argon atmosphere in oven-dried 
glassware using anhydrous solvents from commercial suppliers. Air and/or moisture sensitive 
reagents were transferred via syringe or cannula and were introduced into reaction vessels 
through rubber septa. Solvent removal was accomplished with a rotary evaporator at ca. 10-50 
Torr.  Column chromatography was carried out using a Biotage SP1 flash chromatography 
system and silica gel cartridges from Biotage. Analytical TLC plates from EM Science (Silica 
Gel 60 F254) were employed for TLC analyses.  Microwave heating was accomplished using a 
CEM reaction microwave.  Hydrogenation reactions were carried out with a ThalesNano H-Cube 
hydrogenator.   
 All synthesized analogs tested against CTX-M were judged to be of 95% or higher purity 
based on analytical LC/MS analysis.  LC/MS analyses were performed on a Waters Micromass 
ZQ/Waters 2795 Separation Module/Waters 2996 Photodiode Array Detector system controlled 
by MassLynx 4.0 software.   Separations were carried out on an XTerra® MS C18 5µm 
4.6x50mm column at ambient temperature using a mobile phase of water-acetonitrile containing 
0.05% trifluoroacetic acid.  Gradient elution was employed wherein the acetonitrile-water ratio 
was increased linearly from 5 to 95% acetonitrile over 2.5 minutes, then maintained at 95% 
acetonitrile for 1.5 min., and then decreased to 5% acetonitrile over 0.5 min, and maintained at 
5% acetonitrile for 0.5 min.  Compound purity was determined by integrating peak areas of the 
liquid chromatogram, monitored at 254 nm. 
  General Procedure A. An oven-dried vial or flask is charged with 3-(1H-
tetrazol-5-yl)aniline (1 equiv), the appropriate carboxylic acid (1 equiv), 1-ethyl-3-[3-
	   48	  
dimethylaminopropyl]carbodiimide hydrochloride (1.5 equiv), 1-hydroxybenzotriazole (1.5 
equiv) and N,N’-diisopropylethylamine (2 equiv) and stirred in DMF (0.5 mL) at room 
temperature for 24 h or until judged complete by LC/MS analysis. The reaction mixture is 
diluted with water (2 mL) and after adjusting the pH to ~2 with 1N HCl, the mixture is extracted 
with ethyl acetate. The organic extracts are washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. The crude material thus obtained is purified by reverse 
phase HPLC to afford the desired product. 
  General Procedure B. An oven-dried vial or flask is charged with 3-(1H-
tetrazol-5-yl)aniline (1 equiv), the appropriate acid chloride (1.05 equiv) and N,N’-
diisopropylethylamine (2 equiv) and stirred in dichloromethane (5 mL) at room temperature for 
30 min. The reaction mixture is diluted with dichloromethane and washed with water.  After 
adjusting the pH to ~2 with 1N HCl, the mixture is extracted with ethyl acetate.  The organic 
extracts are washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. The crude material thus obtained is purified by flash column chromatography (5-20% 
methanol/dichloromethane). 
 3-Cyclopropyl-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (5). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available 3-cyclopropylbenzoic acid according to 
general procedure A to afford the title compound in 63% yield; 1H NMR (DMSO-d6) d 10.42 (s, 
1H), 8.55 (s, 1H), 7.93 (d, J = 8 Hz, 1H), 7.72 (d, J = 8 Hz, 2H), 7.65 (s, 1H), 7.56 (t, J = 8 Hz, 
1H), 7.39 (t, J = 8 Hz, 1H), 7.29 (d, J = 8 Hz, 1H), 1.97-2.03 (m, 1H), 0.97-1.01 (m, 2H), 0.74-
0.78 (m, 2H); LCMS (ESI) m/z 306 (MH+). 
 3-Acetyl-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (7). 3-(1H-Tetrazol-5-yl)aniline 
was reacted with commercially available 3-acetylbenzoic acid according to general procedure A 
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to afford the title compound in 33% yield; 1H NMR (DMSO-d6) d 10.67 (s, 1H), 8.57 (s, 1H), 
8.52 (s, 1H), 8.22 (d, J = 8 Hz, 1H), 8.16 (d, J = 8 Hz, 1H) 7.96 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 
Hz, 1H), 7.70 (t, J = 8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 2.65 (s, 3H); LCMS (ESI) m/z 308 
(MH+). 
  N-[3-(1H-Tetrazol-5-yl)-phenyl]-isophthalamic acid methyl ester (9). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available mono-methylisophthalate according to 
general procedure A to afford the title compound in 22% yield; 1H NMR (DMSO-d6) d 10.70 (s, 
1H), 8.56 (s, 2H), 8.25 (d, J = 8 Hz, 1H), 8.16 (d, J = 8 Hz, 1H) 7.96 (d, J = 8 Hz, 1H), 7.68-7.75 
(m, 2H), 7.58 (t, J = 8 Hz, 1H), 3.90 (s, 3H); LCMS (ESI) m/z 324 (MH+). 
 3-Pyrimidin-2-yl-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (11). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available 3-pyrimidin-2-yl-benzoic acid according to  
general procedure A to afford the title compound in 11% yield; 1H NMR (DMSO-d6) d 10.71 (s, 
1H), 8.99 (s, 1H), 8.96 (d, J = 4 Hz, 2H), 8.58-8.61 (m, 2H), 8.14 (d, J = 8 Hz, 1H), 7.99 (d, J = 
8 Hz, 1H), 7.68-7.76 (m, 2H), 7.58 (t, J = 8 Hz, 1H), 7.49 (d, J = 4 Hz, 1H); 13C NMR (100 
MHz, DMSO-d6) d 166.2, 163.3, 158.5, 140.7, 138.1, 135.9, 131.4, 130.7, 130.4, 129.6, 127.7, 
123.6, 122.8, 121.0, 119.3;  LCMS (ESI) m/z 344 (MH+). 
 3-Dimethylaminomethyl-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (12). 3-(1H-
Tetrazol-5-yl)aniline was reacted with commercially available 3-dimethylaminomethyl-benzoic 
acid according to  general procedure A to afford the title compound in 28% yield; 1H NMR 
(DMSO-d6) d 10.60 (s, 1H), 8.57 (s, 1H), 8.08-8.10 (m, 2H), 7.95 (d, J = 8 Hz, 1H), 7.70-7.76 
(m, 2H), 7.58-7.64 (m, 2H), 4.37 (s, 2H), 2.75 (s, 6H); 13C NMR (100 MHz, DMSO-d6) d 165.9, 
140.5, 135.9, 134.8, 131.4, 131.3, 130.5, 129.7, 129.3, 123.5, 122.9, 119.4, 60.0, 42.5;  LCMS 
(ESI) m/z 323 (MH+). 
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 3-Cyano-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (14). 3-(1H-Tetrazol-5-yl)aniline 
was reacted with commercially available 3-cyanobenzoic acid according to general procedure A 
and purified by flash column chromatography (5-15% methanol/ dichloromethane) to afford the 
title compound in 66% yield; 1H NMR (DMSO-d6) d 10.63 (s, 1H), 8.53 (s, 1H), 8.43 (s, 1H), 
8.25 (d, J = 8 Hz, 1H), 8.06 (d, J = 8 Hz, 1H) 7.92 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 2H), 7.56 
(t, J = 8 Hz, 1H); LCMS (ESI) m/z 291 (MH+). 
 1H-Indole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide (15). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available indole-4-carboxylic acid according to  
general procedure A to afford the title compound in 10% yield; 1H NMR (DMSO-d6) d 11.35 (s, 
1H), 10.41 (s, 1H), 8.65 (s, 1H), 7.93 (d, J = 8 Hz, 1H), 7.70 (d, J = 4 Hz, 1H), 7.53-7.62 (m, 
3H), 7.47 (s, 1H), 7.20 (t, J = 8 Hz, 1H), 6.85 (s, 1H); LCMS (ESI) m/z 305 (MH+). 
 3H-Benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide (16). 3-(1H-
Tetrazol-5-yl)aniline (75 mg, 0.47 mmol) , 1H-benzimidazole-4-carboxylic acid (76 mg, 0.47 
mmol), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (135 mg, 0.7 mmol), 1-
hydroxybenzotriazole (95 mg, 0.7 mmol) and N,N’-diisopropylethylamine (0.17 mL, 0.94 mmol) 
were stirred in DMF (0.5 mL) at room temperature for 4 h. The reaction mixture was diluted 
with water (1 mL) and after adjusting the pH to ~4 with 1N HCl, the mixture was filtered. The 
filtered precipitate was purified by reverse phase HPLC to afford the product as a trifluoroacetic 
acid salt in 21% yield. 1H NMR (DMSO-d6) d 11.69 (s, 1H), 9.00 (s, 1H), 8.61 (s, 1H), 8.12 (d, J 
= 8 Hz, 1H), 7.93-7.99 (m, 2H), 7.79 (d, J = 8 Hz, 1H), 7.52-7.63 (m, 2H); 13C NMR (100 MHz, 
DMSO-d6) d 164.1, 159.2, 148.4, 143.4, 140.2, 134.3, 130.8, 125.6, 124.3, 123.1, 122.9, 121.9, 
118.9, 118.4; LCMS (ESI) m/z 306 (MH+). 
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 1H-Indole-5-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide (17). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available indole-5-carboxylic acid according to the 
general procedure A to afford the title compound in 9% yield; 1H NMR (DMSO-d6) d 11.39 (s, 
1H), 10.36 (s, 1H), 8.62 (s, 1H), 8.30 (s, 1H), 7.96 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 7.69 
(d, J = 8 Hz, 1H), 7.45-7.57 (m, 3H), 6.58 (s, 1H); LCMS (ESI) m/z 305 (MH+). 
 1H-Indazole-5-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide (18). 3-(1H-Tetrazol-
5-yl)aniline was reacted with commercially available indazole-5-carboxylic acid according to  
general procedure A to afford the title compound in 6% yield; 1H NMR (DMSO-d6) d 10.50 (s, 
1H), 8.61 (s, 1H), 8.51 (s, 1H), 8.26 (s, 1H), 7.95-7.98 (m, 3H), 7.71 (d, J = 4 Hz, 1H), 7.64 (d, J 
= 8 Hz, 1H), 7.57 (t, J = 8 Hz, 1H); LCMS (ESI) m/z 306 (MH+). 
 6-Trifluoromethyl-3H-benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-
amide (19). 3-(1H-Tetrazol-5-yl)aniline (15 mg, 0.09 mmol) , 6-trifluromethyl-benzimidazole-4-
carboxylic acid (25 mg, 0.09 mmol), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (26 mg, 0.135 mmol), 1-hydroxybenzotriazole (18 mg, 0.135 mmol) and N,N’-
diisopropylethylamine (0.047 mL, 0.27 mmol) were stirred in DMF (0.2 mL) at room 
temperature for 24 h. The reaction mixture was filtered and purified by reverse phase HPLC to 
afford the title compound as a trifluoroacetic acid salt in 30% yield;  1H NMR (DMSO-d6) d 8.78 
(s, 1H), 8.54 (s, 1H), 8.24 (d, J = 12 Hz, 2H), 8.02 (d, J = 8 Hz, 1H), 7.80 (d, J = 8 Hz, 1H), 7.64 
(t, J = 8 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) d 163.1, 155.1, 146.9, 140.0, 130.9, 126.5, 
125.6, 123.8, 123.5, 123.1, 122.3, 119.6, 118.8, 94.6; LCMS (ESI) m/z 374 (MH+). 
 3-Bromo-5-hydroxy-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (20). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available 3-bromo-5-hydroxybenzoic acid according to 
general procedure A to afford the title compound in 22% yield; 1H NMR (DMSO-d6) d 10.48 (s, 
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1H), 10.27 (s, 1H), 8.55 (s, 1H), 7.91 (d, J = 8 Hz, 1H), 7.72 (d, J = 4 Hz, 1H), 7.60 (s, 1H), 7.56 
(d, J = 8 Hz, 1H), 7.34 (s, 1H), 7.15 (s, 1H); LCMS (ESI) m/z 361 (MH+). 
 3-Hydroxy-N-[3-(1H-tetrazol-5-yl)-phenyl]-5-trifluoromethyl-benzamide (21). 3-(1H-
Tetrazol-5-yl)aniline was reacted with commercially available 3-hydroxy-5-trifluoromethyl 
carboxylic acid according to general procedure A to afford the title compound in 24% yield; 1H 
NMR (DMSO-d6) d 10.60 (s, 1H), 10.51 (s, 1H), 8.55 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.74 (d, J = 
12 Hz, 2H), 7.64 (s, 1H), 7.58 (d, J = 8 Hz, 1H), 7.24 (s, 1H); LCMS (ESI) m/z 350 (MH+). 
 3-Amino-N-[3-(1H-tetrazol-5-yl)-phenyl]-5-trifluoromethyl-benzamide (22). 3-(1H-
Tetrazol-5-yl)aniline (75 mg, 0.47 mmol), 3-amino-5-trifluoromethyl-benzoic acid (96 mg, 0.47 
mmol), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride ( 135 mg, 0.7 mmol), 1-
hydroxybenzotriazole (95 mg, 0.7 mmol) and N,N’-diisopropylethylamine (0.16 mL, 0.94 mmol) 
were stirred in DMF (0.5 mL) at room temperature for 18 h. The reaction mixture was filtered 
and purified by reverse phase HPLC to afford the title compound in 52% yield; 1H NMR 
(DMSO-d6) d 10.50 (s, 1H), 8.53 (s, 1H), 7.92 (d, J = 8 Hz, 1H), 7.72 (d, J = 8 Hz, 1H), 7.56 (t, J 
= 8 Hz, 1H), 7.37 (d, J = 8 Hz, 2H), 7.24 (s, 1H); LCMS (ESI) m/z 349 (MH+). 
 6-Fluoro-3H-benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide (23). 
3-(1H-Tetrazol-5-yl)aniline was reacted with commercially available 6-fluoro-benzimidazole-4-
carboxylic acid according to the general procedure A to afford the title compound in 17% yield; ; 
1H NMR (DMSO-d6) d 8.63 (s, 1H), 8.53 (s, 1H), 7.99 (d, J = 8 Hz, 1H), 7.71-7.80 (m, 4H), 7.63 
(t, J = 8 Hz, 1H); LCMS (ESI) m/z 324 (MH+). 
 3-Bromo-5-cyano-N-[3-(1H-tetrazol-5-yl)-phenyl]-benzamide (24). 3-(1H-Tetrazol-5-
yl)aniline was reacted with commercially available 3-cyano-5-bromobenzoic acid according to 
the general procedure A to afford the title compound in 24% yield; ; 1H NMR (DMSO-d6) d 
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10.70 (s, 1H), 8.53 (s, 1H), 8.45 (s, 1H), 8.41 (d, J = 8 Hz, 2H), 7.94 (d, J = 8 Hz, 1H), 7.76 (d, J 
= 8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H); LCMS (ESI) m/z 370 (MH+). 
 2-Amino 3-nitro-5-trifluoromethylbenzoic acid (25). Commercially available 2-chloro-3-
nitro-5-trifluoromethylbenzoic acid (0.10 g, 0.37 mmol) and aqueous ammonium hydroxide (2 
mL) were heated in a sealed tube in a CEM microwave at 120o C for an hour. After cooling, the 
pH was adjusted to 2 with 1N HCl. The precipitate was filtered and dried to obtain 2-amino 3-
nitro-5-trifluoromethylbenzoic acid as a yellow solid (80 mg). This material was used in the next 
step without further purification. 1H NMR (DMSO-d6) d 8.49 (s, 1H), 8.32 (s, 1H). 
 2,3-Diamino-5-trifluromethylbenzoic acid (26).  A solution of 2-amino-3-nitro-5-
trifluoromethylbenzoic acid (25, 75 mg, 0.3 mmol) in methanol was passed through a Pd/C 
cartridge (10 wt%) at a flow rate of 1 mL/min using the H-Cube hydrogenation system. The 
solution was concentrated under reduced pressure and dried to obtain the title compound (62 
mg). This material was used without further purification in the next reaction.  1H NMR (CDCl3) 
d 7.80 (s, 1H), 7.05 (s, 1H); LCMS (ESI) m/z 221 (MH+). 
 6-Trifluromethyl-benzimidazole-4-carboxylic acid (27). Formic acid (0.34 mmol, 3 
equiv) was added to intermediate 26 (0.11 mmol, 1 equiv) in aqueous 4M HCl (0.35 mL) and the 
reaction mixture heated to 100o C for two hours. The reaction mixture was concentrated under 
reduced pressure and dried to obtain the title compound (35 mg) as a hydrochloride salt. This 
material was used without further purification in the next reaction. 1H NMR (DMSO-d6) d 8.74 
(s, 1H), 8.33 (s, 1H), 8.07 (s, 1H); LCMS (ESI) m/z 231 (MH+). 
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Protein Purification 
 The CTX-M9 gene sequence was cloned into the pET9a expression vector and 
transformed into BL21 DE3 competent cells for protein expression.  The cells were cultured in 
2XYT media, containing tryptone (16g/L), yeast extract (10g/L), and NaCl (5.0g/L).  In addition, 
2M sorbitol and 50mM betaine were added to the media.  The cultures were grown in the 
presence of kanamycin and ampicillin.     The cultures were incubated at 37 degrees Celsius with 
shaking at 300 RPM unto the OD600 reached between 0.6 to 0.8, and then were induced by 
adding a final concentration of 0.25 mM IPTG.  The induced cultures were then grown overnight 
at 25 degrees Celsius with vigorous shaking at approximately 250 RPM.  After centrifugation at 
4000g at 4 degrees Celsius, the supernatant was discarded and the pellet was placed in the -80 
degree Celsius incubator for at least 20 minutes.  The cell pellet was then resuspended in lysis 
buffer, containing 10 mM MES (pH 6.0), 2 mM EDTA, and a protease inhibitor tablet was 
added.  The cells were then lysed by sonication, with a duration of sonication for 10 seconds on, 
and 15 seconds off, with a total sonication time of 15 minutes.  The lysate was then centrifuged 
at 15,000 RPM for 25 min at 4 degrees Celsius. The supernatant was then filtered and loaded on 
to an CM (weak cation exchange) Sepharose ion exchange column.   The loading buffer 
contained 50 mM MES (pH 6.0), 2 mM EDTA and the elution buffer was composed of 50mM 
MES (pH 6.0), 2 mM EDTA, and 150 mM NaCl.  The column was washed with loading buffer, 
approximately two column volumes.  The protein was then eluted using a linear gradient of 0-
80% elution buffer, with the protein being eluted at approximately 30 mM NaCl.  Based on the 
SDS PAGE gel results, the protein fractions were pooled and prepared to be loaded onto a size 
exclusion column.  The gel filtration buffer used contained 10 mM Tris (pH 7.0), 50 mM NaCl, 2 
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mM EDTA.   The fractions were pooled and the protein was concentrated to approximately 
20mg ml-1 to be used for crystallization experiments.  
 
Crystallization  
 The protein was crystallized in 1.2-1.6 M potassium phosphate buffer (pH 8.3) from 
hanging drops at 20 °C.  The final concentration of the protein in the drop ranged from 6.5 mg 
ml-1 to 9 mg ml-1.   The complex crystals were obtained through soaking methods.  Based on the 
variability in terms of solubility and affinity, compound soaking times varied considerably, from 
1 hour to 24 hours.   Diffraction was measured at two beamlines: X6A at National Synchrotron 
Light Source, Brookhaven, New York and 23-ID-B of GM/CA CAT at Advanced Photon Source 
(APS), Argonne, Illinois.  Data were processed with HKL2000 (151).   The models for 
refinement were first obtained through using a rigid-body refinement by Refmac in CCP4 (152) 
with an apo CTX-M-9 structure.   CCP4 and Coot (153) were used to complete the model 
rebuilding and refinement.   
 
Inhibition Assays 
 The hydrolysis reaction of CTX-M activity was measured using the β-lactam substrate 
nitrocefin in reaction buffer consisting of 100mM Tris-HCl (pH 7.0, with 0.01% v/v Triton X-
100) and monitored using a Biotek Synergy Mx Monochromator-Based Multi-Mode Microplate 
Reader at 480 nM wavelength (78, 154).  Nitrocefin was 50 µM in the inhibition assays.  The Km 
of nitrocefin for CTX-M was determined to be 24 µM.  The compounds were synthesized as 
previously described or purchased from the company Chembridge, and assayed without further 
purification.  The highest concentrations at which the compounds were tested were up to 1-3 mM 
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(depending on their solubility) in IC50 experiment.  The reaction was initiated by adding protein 
to the reaction buffer last.  
  
Microbiology 
Note to Reader 
 This portion of the chapter was contributed by the Bonnet et al lab and have been 
previously published and has been reproduced with permission from (79)  (Nichols et al., 2012 
American Chemical Society) (see Appendix 4).   
 Susceptibility testing was performed and interpreted following the guidelines of CLSI 
(144). The compounds were dissolved in DMSO, and dilutions were performed using Muller–
Hinton medium. An adequate final concentration was obtained to determine the minimum 
inhibitory concentrations (MICs). The concentration of DMSO was maintained below 10%. The 
inhibitors were tested for synergy with the third-generation β-lactam cefotaxime against two 
clinical bacteria. The ratio of β-lactam to inhibitor was 1:1. Each value reported reflects the 
average of three independent experiments. The bacteria belonged to the species Escherichia coli 
and exhibited high level of resistance to β-lactams because of CTX-M-9 and CTX-M-14 β-
lactamases. 
 For disk diffusion plate assays, bacterial strains were diluted in sterile water to a turbidity 
equivalent to 0.5 McFarland turbidity standards. After a subsequent 10-fold dilution, the 
bacterial suspensions were inoculated on Mueller Hinton agar. The plates were dried for 10 min 
before applying the disks containing cefotaxime antibiotic (30 µg) or the inhibitor (30 µg) or 
both (cefotaxime:inhibitor : 30 µg:15 µg, 30 µg:30 µg) or the solvent. After overnight incubation 
at 37 °C, the zones of bacterial-growth inhibition were measured. 
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Table 1. Analogs Designed to Target Hydrophobic Shelf Formed by Pro167 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Compound        R = Ki (µM) L.E.a LipEb 
1 F 21 0.30 
 
1.37 
2 Cl 6.2 0.34 
 
1.63 
3 Me 4.5 0.35 1.84 
4 Br 3.0 0.36 1.74 
5 cyclopropyl 3.1 0.33 1.74 
6 OMe 17.1 0.30 1.95 
7 Ac 10.2 0.30 2.51 
8 NO2 3.8 0.32 2.45 
9 CO2Me 6.9 0.29 2.09 
10 CF3 2.4 0.32 1.73 
11 2-pyrimidyl 9.7 0.26 1.57 	  
a LE, ligand efficiency; ΔGbind(kcal)/(Number of heavy atoms). b LipE = pKi – clogP (clogP calculated using 
MarvinSketch 5.5.0.1). 
 
  
H
N
O
NN
N
N R
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Table 2. Analogs Designed to Target Asp240 
 
 
 
 
 
 
Compound        R = Ki (µM) L.E.a LipEb 
12  76.0 0.23 2.22 
13 
 
no inhibition N/A N/A 
14 
 
7.2 0.32 2.27 
15 
 
6.6 0.31 2.05 
16 
 
1.3 0.35 3.58 
17 
 
1.9 0.34 2.59 
18 
 
1.1 0.35 3.55 
 
a LE, ligand efficiency; ΔGbind(kcal)/(Number of heavy atoms). b LipE = pKi – clogP (clogP calculated using 
MarvinSketch 5.5.0.1). 
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N
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Table 3. Analogs Designed to Target Both Pro167 and Asp240 
 
 
 
Compound R = Ki (µM) L.E.a LipEb 
19 
 
0.089 0.36 3.86 
20 
 
0.57 0.39 2.74 
21 
 
0.63 0.34 2.59 
22 
 
1.0 0.33 2.89 
23 
 
2.7 0.32 3.11 
24 
 
34.1 0.26 0.83 
 
a LE, ligand efficiency; ΔGbind(kcal)/(Number of heavy atoms). b LipE = pKi – clogP (clogP calculated using 
MarvinSketch 5.5.0.1). 
H
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Figure 14.  Crystal Structure of Compound 1 in Complex with CTX-M-9 (75).  
Compound 1 (Ki = 21 µM) carbon atoms are shown in yellow, nitrogens in blue, 
oxygens in red, and fluorine in light blue.  The dashed lines represent hydrogen bonds 
with a sphere representing a water molecule.   
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(b)	  
(a)	  
(c)	  
Figure 15. Crystal Complex Structures with Compounds Targeting Pro167.  
 (a) Compound 4. (b) Compound 10. (c) Compound 11.  The red dashed lines represent 
hydrogen bonds between the ligand and CTX-M-9.  The carbon atoms of the protein are 
colored in green along with oxygens in red and nitrogens in blue.  The ligand carbon 
atoms are colored yellow.  Resolution for the structures ranges from 1.2-1.4 Å.  Unbiased 
Fo-Fc densities are shown in blue at 3 σ. 
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(a)	  
(b)	  
(c)	  
Figure 16. Crystal Complex Structures with Compounds Targeting Asp240.   (a) 
Compound 18. (b) Compound 16. (c) Compound 12, in comparison to the designed pose 
in cyan.  The red dashed lines represent hydrogen bonds between the ligand and CTX-M-
9.  The carbon atoms of the protein are colored in green along with oxygens in red and 
nitrogens in blue.  The ligand carbon atoms are colored yellow.  Resolution for the 
structures ranges from 1.2-1.4 Å.  Unbiased Fo-Fc densities are shown in blue at 3 σ. 
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Cefotaxime:inhibitor 
30µg:0µg 
Cefotaxime:inhibitor 
30µg:15µg 
Cefotaxime:inhibitor 
30µg:30µg 
15µg inhibitor 30µg inhibitor 0µg inhibitor 
Figure 17. Disk Diffusion Plate Assay Showing the Antimicrobial 
Activity of Compound 19.  The compound was administered alone or in 
combination with cefotaxime against a E. coli strain producing CTX-M-9 β-
lactamase.  
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Chapter 3 
 
Proton Transfer and Short Hydrogen Bond Formation Induced by Ligand Binding in  
Serine β-lactamase Catalysis 
 
Overview 
 Ligand binding can change the pKa of protein residues and influence enzyme catalysis.  
Here we report three sub-Angstrom resolution X-ray crystal structures of CTX-M β-lactamase, 
representing three stages of the enzymatic pathway: apoprotein (0.80 Å), pre-covalent complex 
(0.89 Å) and acylation transition state analog (0.85 Å).  The binding of a non-covalent ligand 
induces a proton transfer from the catalytic Ser70 to the general base Glu166, and the formation 
of a low-barrier hydrogen bond (LBHB) between Ser70 and Lys73.  This LBHB is absent in the 
other two structures.  Our data represent the first evidence of a direct and transient LBHB 
stabilizing a nucleophilic serine, as hypothesized by Cleland and Kreevoy.  These results have 
important implications for enzyme mechanisms and modeling of protein-inhibitor interactions.   
 
Introduction 
 The protonation states of protein side chains dictate their roles in enzyme catalysis and 
inhibitor binding.  Such information, while vital to the studies of enzyme mechanism and drug 
discovery, is challenging to determine experimentally, especially for transient reaction 
intermediates. In particular, the binding of small molecules often results in alterations in the 
protein microenvironment and consequently in the pKa of catalytic residues. Such effects can 
potentially promote proton transfer in the pre-covalent Michaelis complex during general 
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base/acid catalysis.  They may also induce the formation of a low barrier hydrogen bond 
(LBHB), where two functional groups with closely matched pKa’s share a proton equally, 
contributing to an unusually short (~2.5 Å) and strong hydrogen bond (HB) (155).   However, 
due to experimental difficulties and particularly the challenge of identifying hydrogen atom 
positions, the investigation of proton transfer and LBHB has suffered from a lack of structural 
evidence by X-ray crystallography, despite indirect support from both experiments (156) and 
computational calculations (157) .    
CTX-M Class A β-lactamase, a member of the serine hydrolase superfamily, provides a 
suitable system to investigate these questions both because its crystals can diffract to sub-
Angstrom resolution and because small molecule inhibitors are available to trap relevant reaction 
intermediates.  As the most common clinically-observed extended spectrum β-lactamase, CTX-
M has enhanced activity hydrolyzing and deactivating third-generation cephalosporins, aside 
from other β-lactam antibiotics such as penicillins (14, 17).  The reaction consists of an acylation 
step followed by a deacylation step, both involving proton transfer facilitated by general-
acid/base catalysis.  During the acylation process, Ser70 is deprotonated prior to its attack on the 
substrate, and a proton is subsequently transferred to the leaving nitrogen on the substrate, 
accompanying the formation of a covalent acyl-enzyme bond.  In the deacylation reaction, a 
general base removes a proton from the catalytic water before it reacts with the acyl-enzyme 
linkage, leading to the release of the hydrolyzed product and the regeneration of the enzyme.  
One of the key questions that has persisted in the studies of Class A β-lactamases is the identity 
of the catalytic base during acylation, with both Lys73 and Glu166 proposed to assume this role 
(24, 84, 85, 158-160).  In one of the most comprehensive models, Mobashery and colleagues 
used quantum mechanics/molecular mechanics (QM/MM) calculations to illustrate that upon 
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substrate binding, Ser70 loses its proton to the negatively charged Glu166 through the mediating 
catalytic water, whereas concurrently the positively charged Lys73 donates one of its protons to 
Ser70, resulting in a pre-covalent intermediate with all three residues in a neutral state (161).  
The neutral Lys73 will then deprotonate Ser70 before the nucleophilic serine attacks the β-
lactam ring (161).  Whereas this hypothesis can potentially reconcile the seemingly contradicting 
experimental data concerning the acylation reaction, the transient nature of the Michaelis 
complex makes it challenging to verify experimentally (Fig. 18).  
Our most recent development of a high-affinity non-covalent CTX-M inhibitor, which 
interacts with many of the same key residues as the β-lactams, offers a rare opportunity to mimic 
the pre-covalent complex (79).  We have determined three sub-Angstrom resolution X-ray 
crystal structures of CTX-M-14, representing three stages of the enzymatic pathway: apoprotein 
(0.80 Å), pre-covalent complex (0.89 Å), and acylation transition state analog (0.85 Å).  Many 
hydrogen atoms, including some on the ligands, can be identified using unbiased Fo-Fc 
difference maps (Fig. 19a-b).  More importantly, all hydrogen atoms on polar functional groups 
can be identified in the active site, except for Lys73 in the covalent complex (Fig. 20a-c).  When 
comparing the three structures, the Lys73 is most apparent in its conformational changes, along 
with the catalytic water (Fig. 20d).  These observations are consistent between the two 
monomers in the asymmetric unit of the P21 space group and between data sets from different 
crystals obtained at similar resolutions. 
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Results 
In the apo structure, Lys73 functions as a HB donor to Ser70, which in turn acts as a HB 
donor to the catalytic water (wat1, Fig. 20a).  The water shares its own proton with a negatively 
charged Glu166. These observations agree with the previously determined 0.88 Å resolution X-
ray crystal structure of CTX-M-9, as well as the 0.90 Å resolution SHV-2 structure (20, 85).  It 
demonstrates that Glu166, together with the catalytic water, may serve as the general base to 
deprotonate Ser70 prior to the attack on the substrate, as suggested by mutagenesis and 
theoretical calculations (161, 162).   
This hydrogen-bonding network however, is altered in the non-covalent complex (Fig 
20b).  The proton shared between the catalytic water and Glu166 is now bonded to the protein 
side chain, and the hydrogen originally on Ser70Oγ is transferred to the catalytic water.  The net 
effect of these changes is a proton transfer from Ser70 to the general base Glu166, making 
Glu166 neutral and Ser70 at least partially negatively charged.  The change in side chain charges 
may partially explain the small movement of the Lys73 side chain away from Glu166 and closer 
to Ser70, establishing a short hydrogen bond with a length of 2.53 Å.  Interestingly, the hydrogen 
atom shared between Lys73 and Ser70 appears to be located near the center between the two 
heteroatoms.  This hydrogen atom is even visible in the 2Fo-Fc map together with several highly 
ordered riding hydrogen atoms such as those on Ser70Cβ (Fig 21a).  From the 2Fo-Fc map, the 
proton is 1.3 Å away from both Lys73Nζ and Ser70Oγ, suggesting that the HB between the two 
residues is potentially a LBHB.   Ser70 also functions as an acceptor in a third HB with a water 
molecule in the oxyanion hole (wat4), with a HB length of 2.59 Å, in comparison to 2.85 Å in 
the apo structure.  This interaction further stabilizes the partially negatively charged Ser70 and 
may be one of the reasons allowing for the trapping of the LBHB.      
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In the covalent complex mimicking the acylation transition state, Ser70 becomes 
covalently linked to the boron atom of the inhibitor (Fig. 20c).  Glu166 remains neutral.  Lys73 
moves away from Ser70 and closer to Ser130, which is involved in the proton relay process to 
transfer a proton to the ring nitrogen on the substrate, mimicked by the boron oxygen.  Compared 
with the apo and non-covalent complex, the hydrogen atoms on Lys73Nζ are more disordered 
probably due to the weaker hydrogen bonding interactions as suggested by the longer HB 
lengths. The alteration in Glu166 protonation state is consistent with the change in its Cδ-Oε1 
bond length, which is 1.26 Å in the apo structure and 1.31 Å in the two complex structures, 
respectively.  In addition to the unusually short hydrogen bond observed between Ser70 and 
Lys73 in the non-covalent complex, the HB formed between Glu166 and the catalytic water 
appears to be short as well in both the non-covalent and covalent complexes, which has a HB 
length of 2.55 Å.  The hydrogen appears to be covalently bonded to Glu166.  It is also less 
ordered than the hydrogen between Ser70 and Lys73, as it is only visible in the Fo-Fc map and 
not in the 2Fo-Fc map.   
   
Discussion 
The protonation state change of Glu166 in the non-covalent complex agrees with the 
results of the QM/MM calculations by Mobashery and colleagues, highlighting the increasing 
sophistication and maturity of computational methods in making meaningful predictions for 
enzyme analysis (161).  Although the previous study did not investigate the identity of the 
potential LBHB between Ser70 and Lys73, their results indicated that the HB length can be as 
short as 2.5 Å.  More significantly, the calculations revealed that the charged (Lys73-NH3)+-
(Ser70-O)- pair will convert to a neutral (Lys73-NH2)-(Ser70-OH) state in the non-covalent 
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complex, which will then undergo a charge separation back to the (Lys73-NH3)+-(Ser70-O)- pair 
as Ser70 attacks the substrate (161).   The inter-conversion between the two states suggests that 
Ser70 and Lys73 may share the proton equally in the HB between the two in the transient pre-
covalent complex.  The protonation states of these catalytic residues in our non-covalent 
complex are also captured by our own computational studies.   QM/MM reaction path 
calculations seem to confirm the location of the hydrogen (i.e., between Ser70 – Lys73). Further, 
energetic analysis using density functional theory (DFT, wB97X-D/6-31G*) yields an energetic 
barrier to hydrogen transfer of just 1.06 kcal/mol, well under the threshold that typically 
indicates a LBHB.  
The LBHB between Ser70 and Lys73 suggests the importance of Lys73 for the 
stabilization of the nucleophilic serine in preparation for its attack on the β -lactam substrate.   It 
has long been hypothesized that LBHB can lower the energy barrier of enzymatic reactions by 
supplying free energy of up 10 to 20 kilocalories per mole, significantly higher than a standard 
HB of approximately 3-5 kcal/mol (155, 163).   The existence of such LBHBs in proteins 
however, has been subject to intense debate, partly due to the lack of direct observation by X-ray 
crystallography.  Our structures not only represent the first instance of such a LBHB, but also 
demonstrate that ligand binding itself can induce the formation of a LBHB.  Whereas we 
acknowledge that the crystalline environment can be different from the solution, the fact that the 
LBHB is observed only in one out of the three structures suggests that a suitable 
microenvironment is necessary and sufficient for LBHB formation.  Ultrahigh resolution X-ray 
crystal structures have been determined for other serine-based enzymes previously, such as the 
0.78 Å apo subtilisin and 0.83 Å α-lytic protease bound by a covalent boronic acid inhibitor 
(164, 165).  But in each of these previous cases, the proposed LBHB was shown to be a standard 
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HB, similar to our apo and covalent complex, consistent with the transient nature of such LBHBs 
in enzyme catalysis.   One important contributing factor for LBHB formation is the desolvation 
of the active site.  Despite the observation of two structural waters including the catalytic water 
bound by the catalytic residues, the binding of the non-covalent ligand completely isolates the 
CTX-M active site from the bulk solvent, as illustrated by the loss of the HB between the 
catalytic water (wat1) and the water molecule (wat3) closer to the bulk solvent in the apo 
structure.  Additionally, the binding of both the non-covalent and covalent inhibitors caused a 
slight contraction of the active site, as shown by the small movement of the catalytic water (1.2 
Å) and Glu166/Asn170 (0.5-0.6 Å) (Fig. 20d).  This slightly higher compactness of the active 
site squeezes out the water (wat2) shared by Lys73 and Glu166 in the apo structure.   While 
necessary, the desolvation effect itself is not sufficient for LBHB formation.  Our structures 
suggest that the pre-covalent complex, instead of the tetrahedral transition state, may provide the 
other electrostatic requirements, at least for Class A β-lactamases based on the the evidence of 
proton positions induced by the non-covalent ligand.     
  For serine-based enzymes, Cleland and Kreevoy previously hypothesized that a direct 
LBHB between the general base and the nucleophilic serine can stabilize the activated serine 
during its attack on the substrate, while conceding that this LBHB might be difficult to capture 
by experiment due to its transient nature (155).   The LBHB in our non-covalent complex offers 
the first example of such a LBHB, with a slight twist.   In the acylation process, the functions of 
serine deprotonation and stabilization by LBHB appear to be performed by Glu166 and Lys73 
separately.  However, if we only consider the neutral (Lys73-NH2)-(Ser70-OH) intermediate and 
the fact that Lys73 will regain its proton in the acylation transition state, Lys73 is the de facto 
general base and clearly plays a more important role in this process.  In fact, a neutral Lys73 has 
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been shown by biochemical analysis and NMR to function as general base for acylation in 
E166A mutants of Class A β-lactamases like TEM-1, as well as in penicillin-binding proteins 
(PBPs), the bacterial target of β-lactam antibiotics (24, 166).  Serine β-lactamases have evolved 
from PBPs and the two groups of enzymes often share the same catalytic residues (167).  One of 
the only and notable exceptions is Glu166, which is unique for Class A β-lactamases and 
essential for their ability to catalyze the deacylation step of the β-lactam hydrolysis reaction.  As 
previously discussed by others, the role of Glu166 in the complicated acylation mechanism may 
have been an evolutionary relic or by-product instead of a catalytic necessity (167). Because 
Glu166 is neutral in the non-covalent complex, its influence on the pKa values of neighboring 
residues is diminished.  It is highly likely that the electrostatic microenvironment of the pre-
covalent Michaelis complex is very similar between Class A β-lactamases and PBPs.   We 
therefore hypothesize that the LBHB between the equivalents of Ser70 and Lys73 may also play 
an important role in the catalysis of PBPs including their inhibition by β-lactam antibiotics.  
Morever, as nucleophilic serine is used to catalyze a wide range of enzymatic reactions by 
forming a covalent intermediate with the substrate, it is possible that similar LBHBs are present 
in other enzymatic reaction, as previously hypothesized (155, 163).  
The studies of LBHBs have so far only focused on their potential contribution to enzyme 
catalysis. In addition to the Ser70-Lys73 LBHB in the active site, we have observed a LBHB in a 
partially buried region of the CTX-M protein between Asp233 and Asp246, present in both the 
apo and complex structures.  Again, we are able to observe the hydrogen shared by these two 
residues in the 2Fo-Fc density map, with a distance of 2.47 Å between the two heteroatoms (Fig. 
21b).  Asp233 and Asp 246 are highly conserved in Class A β-lactamases.  Based on the HB 
distance between these two residues, it appears that the LBHB may be present in many other 
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Class A β-lactamases.  Because the two aspartate residues are located outside the active site, we 
suspect that the LBHB may be important for protein stability.  Interestingly, in a few enzymes 
where Asp246 is replaced by isoleucine, an alternative short hydrogen bond is formed between 
Asp233 and Asp214 (Asn in CTX-M, data not shown).  It should be noted that proton-mediated 
Asp-Asp pairs are commonly observed in proteins with some hypothesized to play a catalytic 
role as well.   These observations, together with previous studies on enzymes such as HIV 
protease, suggest that LBHB may play a common role in protein structure and function. 
Aside from the valuable insights into enzyme mechanism, our results, specifically the 
protonation state change induced by ligand binding, have important implications for drug 
discovery, particularly computational modeling of protein-ligand interactions.  Non-covalent 
inhibitors are usually the focus of many drug development efforts, mainly structure-based 
approaches.  It is often assumed that inhibitor binding does not change the protonation state of 
residues in the target binding site, especially those side chains that do not form a direct HB with 
the ligand.  Neither Ser70, Lys73 or Glu166 establishes a HB with our non-covalent inhibitor, 
yet the protonation states of all three residues are affected by ligand binding.  Additionally, there 
is no net proton gain/loss in the active site during the binding event, so the protonation state 
changes may not be captured by indirect methods such as isothermal titration calorimetry.  Both 
the experimental and computational data presented here suggest that molecular docking may 
potentially benefit from QM/MM methods in analyzing possible protonation change upon ligand 
binding, as such changes will significantly affect the calculations of protein-ligand interactions. 
In addition, we have recently made the E166A mutant of CTX-M14 and have obtained 
preliminary structures of apo and non-covalent complex at 1.05 and 0.89 Å respectively (Fig. 
22a-b).  In the mutant apo structure, Lys73 adopts a different confirmation compared to that of 
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the wild type, in which the mutant structure has its Lys73 end group pointed upward (Fig. 22a), 
as opposed to the wild type orientation in which this end group is pointed toward the Glu166.  In 
the mutant apo structure, the catalytic water is missing, with only residual electron density 
nearby, indicating a very low-occupancy water.  These results are consistent with a previously 
determined mutant of E166A for an apo Toho-1 mutant structure, a closely related class A β-
lactamase, determined by neutron diffraction, in which the catalytic water is also missing.    On 
the other hand, this water becomes much more evident in the complex structure and is different 
from the catalytic water in the wild type structure based on the evidence that there is now a 
hydrogen bond formed with the Nδ2 atom of Asn170 instead of Oδ1 as observed in the wild type 
structure.  Interestingly, a short hydrogen bond is observed in the complex mutant structure, with 
a distance between the Lys73 and Ser70 heteroatoms of approximately 2.56 Å (Fig. 22b).  The 
distance between these heteroatoms in the apo mutant structure is considerably larger, with a 
distance of 2.95 Å (Fig. 22a).  When viewing the preliminary data,  a hydrogen in the Fo-Fc is 
located near the middle, between Lys73 and Ser70, indicated a possible LBHB formed, even in 
the absence of Glu166 (data not shown).  Although further refinement is still under progress, our 
results will help elucidate the potential functions of PBPs, from which β-lactamases are 
suggested to have evolved.  Surprisingly, the formation of a short HB in the E166A complex 
structure is still observed, despite the varying Lys73 conformations in the wild type and the 
mutant CTX-M apo structures.  Although Glu166 is absent, the presence of the ligand still 
induces a change in the microenvironment of the active site, which is conducive to the formation 
of a short and possible LBHB.   With regards to the mutant E166A, the question remains as to 
the identity of the catalytic base, whether it is the Lys73 or the newly positioned water molecule 
in which the hydroxide from the bulk solvent can serve the same role.  In order to answer these 
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questions, future experiments to be performed such as NMR, higher resolution x-ray 
crystallographic structures, and neutron diffraction can assist in providing the solutions.   Also, 
the current refinement of the recently acquired ultra high resolution structures may be able to 
more accurately pinpoint the position of these hydrogen atoms.   
 
Conclusions 
In summary, the three sub-Angstrom resolution structures of CTX-M represent the first 
example of any protein whose apo and complex structures have captured protonation state 
changes induced by ligand binding.  They demonstrate the potential of ultrahigh resolution X-ray 
crystallography in investigating important biochemical questions at the level of hydrogen atoms, 
at a time when advancement in crystallization techniques and X-ray hardware has led to 
significant improvement in diffraction resolution for many macromolecular crystals including 
membrane proteins.  Impressively, these protonation state changes were first predicted through 
computational methods (168), and subsequently confirmed and further analyzed by our own 
calculations.  The agreement between theory and experiment highlights the advancement of 
computational chemistry and their increasing utility in elucidating details of chemical reactions 
that are otherwise difficult to investigate experimentally.   The most interesting observation in 
our crystal structures is the LBHB between Ser70 and Lys73, the first LBHB whose hydrogen 
atom is observed by X-ray crystallography and confirmed by QM/MM calculations.  Although 
these studies cannot resolve all the controversy surrounding the role of LBHB in enzyme 
catalysis, they suggest that LBHB can be induced by the right microenvironment in proteins.  
More specifically, they seem to confirm a hypothesis by Cleland and Kreevoy (155) two decades 
earlier that a transient and direct LBHB can be used to stabilize an activated nucleophilic serine 
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in its attack on the substrate.  These results provide a better understanding of the catalytic 
pathway by serine β-lactamases, and allude to similar mechanisms in PBPs and other serine-
based enzymes.   Lastly, the protonation state change induced by both non-covalent and covalent 
inhibitors have important implications for how we simulate protein-ligand interactions in 
molecular docking and may lead to better performance of structure-based approaches in drug 
discovery.   
 
Material and Methods 
 Protein Purification, Crystallization and Structure Determination.  CTX-M-14 was 
used to represent the CTX-M family.  The wild type CTX-M14 protein was purified as 
previously described and crystallized in 1.0-1.2M potassium phosphate buffer (8.3) from hanging 
drops at 20°C.  The final concentration of the protein in the drop ranged from 6.5 mg ml-1 to 10 
mg ml-1.  The non-covalent complex crystals were obtained through soaking methods, with 
soaking times ranging from approximately 24 to 48 hours.  The complex crystals with the 
boronic acid inhibitor LP06 was grown in complex with the protein, with the final concentration 
of the compound in the drop at 5.0 mM.  Diffraction was measured at two beamlines:  8.3.1 at 
Advanced Light Source (ALS), Berkeley, California and 23-ID-B of GM/CA CAT at Advanced 
Photon Source (APS), Argonne, Illinois.  Data were processed with HKL2000.  The apo and 
complex structures were refined with SHELX97 (169).  SHELX97 (169) and Coot (153)  were 
used to complete the model rebuilding and refinement.   	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Figure 18.  The Acylation Half –Reaction for the Class A β-lactamase Reaction Pathway.  
Beginning with the apo class A β-lactamase hydrogen bonding network (i) to a ground-state 
Michaelis complex (ii), as hypothesized by Mobashery et al based on QM/MM calculations (168).  
The remaining stages of catalysis (stages not shown) proceeds through a high-energy acylation 
transition state, to a low-energy acyl-enzyme intermediate  Subsequently, deacylation proceeds 
through a high-energy transition state and on to a post-covalent product complex.   
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Thr235	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Pro167	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Ser130	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Lys73	  
Figure 19.  Complex Structures of CTX-M β-lactamase. The 2Fo-Fc (blue) and Fo-Fc (red) 
electron density maps or the ligands are contoured at 1.5 and 1 σ respectively.  The positive 
difference peaks indicate the positions of hydrogen atoms. (a) A non-covalent complex with a 
novel tetrazole-based inhibitor. The catalytic machinery, including Ser70 and Lys73, is directly 
behind the ligand. (b) A covalent acylation transition state analog using a boronic acid inhibitor.   	  
a)	   b)	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Figure 20.  Proton Transfer and Short Hydrogen Bond Formation Induced by Ligand Binding.  Only the 
catalytic residues are shown. Wat1 is the catalytic water. The positive Fo-Fc peaks (red) indicate the positions of 
hydrogen atoms. (a) Apo structure at 0.8 Å. (b) non-covalent complex structure at 0.89 Å. The proton between 
Ser70 and Lys73 is assigned to the latter for convenience. (c) covalent complex structure at 0.85 Å. Lys73 is 
charged but the hydrogen atoms are not observed in Fo-Fc electron densities.  (d) Three structures superimposed, 
showing the movement of Lys73 (apo, magenta; non-covalent complex, yellow; covalent complex, cyan). 	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a)	   b)	  
Figure 21.  Hydrogen Atoms Captured in 2Fo-Fc Electron Density Maps. The small isolated 
peaks indicate some very ordered hydrogen atoms on carbon atoms and two involved in LBHB. 
The maps are contoured at 0.5 σ to show the center of those peaks for LBHB hydrogens and to 
eliminate background noise. More protons can be identified in Fo-Fc maps (a) LBHB between 
Lys73 and the catalytic Ser70 in the active site. (b) LBHB involving Asp233 and Asp246 partially 
buried.    
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Figure 22.   Preliminary Structures of E166A Mutant. 
(a) apo. (b) non-covalent complex.  Note the formation of 
a short hydrogen bond in the complex. 
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Chapter 4 
 
Summary 
 
 The serine β-lactamases are one of the main causes of bacterial resistance against the β-
lactam antibiotics.  These resistance mechanisms can be overcome by drug therapies, which 
combine the use of β-lactamase inhibitors with β-lactams.  On the other hand, the current 
clinically approved β-lactamase inhibitors, as well as many of those undergoing clinical trials, 
function as mechanism-based suicide  substrates, in which the majority contain a β-lactam ring, 
making them susceptible to hydrolysis by these rapidly evolving β-lactamases.  As a result, the 
need for novel β-lactamase inhibitors is critical to rescue the effectiveness of the historically 
successful use of β-lactam antibiotics targeting multi-drug-resistant bacterial strains.  The 
advantage of using non-covalent inhibitors allows for the sampling of unexplored chemical space 
that has been relatively untouched with the use of traditional β-lactam containing compounds.  
The fragment-based, structure-guided platform we have used represents one of the best 
approaches to develop novel non-covalent compounds, as demonstrated by our lead compound, 
the first nM non-covalent inhibitor against any serine β-lactamase.  The elaboration of these 
novel non-covalent inhibitors allows for the potential to develop more potent compounds that are 
effective against a wide range of clinically relevant β-lactamases.   
 The use of ultra high resolution x-ray crystallography has proven to be a valuable tool for 
studying the class A β-lactamases in their most intricate atomic detail, from novel drug design to 
enzyme catalysis.   Our recent studies of the catalytic mechanism for CTX-M β-lactamase have 
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answered some important questions with regards to the progression of the initial stages of the 
enzyme mechanism, from the apo to the acylation transition state.  More importantly, we have 
been able to characterize the proton transfer process and hydrogen bonding network during these 
intermediate stages.  The methods used to capture these stages of the pathway have paved the 
way for future studies to determine the detailed proton transfer process that occurs during the 
later stages of the reaction, from deacylaction to the enzyme product complex.   The results have 
been able to reveal that ligand binding can change the pKa of protein residues and influence 
enzyme catalysis.  Specifically, the three sub-Angstrom resolution structures of CTX-M 
represent the first example of any protein whose apo and complex structures have captured 
protonation state changes induced by ligand binding.  The role of LBHBs in enzyme catalysis 
has remained relatively elusive and has been intensely debated since Cleland first proposed it in 
1994 (155).  Prior to our discovery of this phenomenon in our structures, not a single example of 
a LBHB was been unambiguously identified in protein structures, mainly due to the transient 
characteristics of LBHBs in enzymatic reactions and the requirement to determine the positions 
of hydrogen atoms.  The results help provide a better understanding of how LBHBs may 
contribute to enzyme stability and catalysis in general, aid in future computational efforts, and 
extend our knowledge of and approaches to other similar proteins, particularly of the serine 
hydrolase family.  
Through the use of ultra high resolution x-ray crystallography, CTX-M β-lactamase 
provides the first model system to answer these questions, due to the ability of the protein to 
diffract at some of the highest resolutions for any enzyme, along with the successes of using our 
novel inhibitor complexes in order to trap the relevant reaction intermediates.   With potential 
advancements in synchrotron x-ray sources, detector improvements, and optimization of crystal 
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quality and lattice packing, future efforts can push the resolution to some of the highest levels 
observed for any enzyme with this model system, eventually leading to the possibility of being 
able to observe lone electron pairs.  Overall, the results obtained from this study have provided 
some valuable insights from a drug design perspective in order to combat antibiotic resistant 
bacterial strains as well as understanding the complex mechanism by which these rapidly 
evolving enzymes function.   
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Appendix 5 
 
β-Lactamase Cloning Constructs 
Gene	   Vector	   Antibiotic	  
Resistance	  
Tags	  CTX_M9	   pET9a	   Kanamycin	   N/A	  CTX-­‐M9	   P0DC29	   Ampicillin	   N-­‐Terminal	  6-­‐His	  (TEV)	  CTX-­‐M9	  optimized	   Pj401(DNA2.0)	   Kanamycin	   N/A	  CTX-­‐M14	   pET9a	   Kanamycin	   N/A	  CTX-­‐M27	   pET9a	   Kanamycin	   N/A	  TEM-­‐1	   pET15-­‐MHL	   Ampicillin	   N/A	  TEM-­‐1	   palterex2	   Ampicillin	   N/A	  SHV-­‐2	   pET15-­‐MHL	   Ampicillin	   N/A	  KPC-­‐2	   pET15-­‐MHL	   Ampicillin	   N/A	  NDM-­‐1	   SUMO	   Ampicillin	   SUMO,	  N-­‐Terminal	  6-­‐	  His	  NDM-­‐1	   MBP	   Ampicillin	   MBP,	  	  N-­‐Terminal	  6-­‐His	  CTX-­‐M9	  A219C	  Mutant	   pET9a	   Kanamycin	   N/A	  CTX-­‐M9	  P99H	  Mutant	   pET9a	   Kanamycin	   N/A	  CTX-­‐M14	  E166Q	  Mutant	   pET9a	   Kanamycin	   N/A	  CTX-­‐M14	  E166A	  Mutant	   pET9a	   Kanamycin	   N/A	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Appendix 6 
 
Compounds Tested Against CTX-M9 
 
Name Ki (µM) Structure 
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Appendix 6 continued 
 
Name Ki (µM) Structure 35-­‐050A	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Appendix 6 continued 
 
Name Ki (µM) Structure 8895429	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N
O
Cl
 9044446	  
 
2.4 NN
N
N
H
N
O
CF3
 9045092	  
 
6.2 NN
N
N
H
N
O
Cl
 9043678	  
 
3.0 NN
N
N
H
N
O
Br
 SMDC	  530564	  Erica	   300 NHNNN
N
O
F
 SMDC	  530563	  	   No	  Inhibition	  
NN
N
N N
H
O
F 	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Appendix 6 continued 
 
Name Ki (µM) Structure SMDC	  530581	  
 
	  No	  Inhibition NNN N NH
O
F  SMDC	  530582	  
 
	  4.5 NNN N HN
O  SMDC	  530583	  
 
17.1 NN
N
N
H
N
O
O
 SMDC	  530592	  
 
1.1 NN
N
N
H
N
O
N
NH
 SMDC	  530593	  
 
1.3 NN
N
N
H
N
O HN
N
 SMDC	  530600	  	  
 
	  No	  Inhibition. NNN N HN
O
N
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Appendix 6 continued 
 
Name Ki (µM) Structure SMDC	  530604	  
 
	  6.9 NNN N HN
O
O
O  SMDC	  530605	  
 
10.2 NN
N
N
H
N
O
O  SMDC	  530606	  	   34.1 NNN
N
H
N
O
Br
N
 SMDC	  530607	  
 
3.8 NN
N
N
H
N
O
N
O
O  SMDC	  530608	  
 
6.3 NN
N
N
H
N
O
Cl
 701759	  
 
No	  Inhibition NNN N
N
H
O
Br
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Appendix 6 continued 
 
Name Ki (µM) Structure 701760	  
 
7.2 NN
N
N
H
N
O N  701761	  
 
6.6 NN
N
N
H
N
O
NH
 701762	  
 
1.9 NN
N
N
H
N
O
NH
 701763	  
 
No	  Inhibition	   NNN
N
H
N
O
F
F
 701764	  
 
2.7 
NN
N
N
H
N
O
N
HN
F
 701765	  
 
0.568 
NN
N
N
H
N
O
OH
Br
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Appendix 6 continued 
 
Name Ki (µM) Structure 701766	  
 
20.2 NN
N
N
N N
H
N
O
F
 735487	  
 
0.0885 
NN
N
N
H
N
O
CF3
N
HN
 730971	  
 
0.628 
NN
N
N
H
N
O
CF3
OH
 730972	  
 
1.0 
NN
N
N
H
N
O
CF3
NH2
 730973	  
 
3.1 NN
N
N
H
N
O  757126 3.3 NN
N
N
H
N
O
NHN
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Appendix 6 continued 
 
Name Ki (µM) Structure 757127 14.3 NN
N
N
H
N
O
NO
 757128 5.5 NN
N
N
H
N
O
N
N
 757129 1.2 NN
N
N
H
N
O
NH
 757229 No	  Inhibition 
NN
N
N
H
N
O
N
N
 757230 12.2 NN
N
N
H
N
O
N
H
N
 835112	   5.0	   NN
N
N
H
N
O
NH
Br 	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Appendix 6 continued 
 
Name Ki (µM) Structure 837810 48.0	   
  837820 No	  Inhibition  
873858 No	  Inhibition  
873886 No	  Inhibition  
 
 
NN
N
N
H
N
O CF3
